cbs-psp-daily-action-plan

CBS/PSP Daily Action Plan

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">cbs-psp-daily-action-plan</th>
</tr>
<tr>
<td class="label">Time</td>
<td>Medication/Supplement</td>
</tr>
<tr>
<td class="label">6:30 AM</td>
<td>Wake-up medications</td>
</tr>
<tr>
<td class="label">7:00 AM</td>
<td>Levodopa (if prescribed)</td>
</tr>
<tr>
<td class="label">7:30 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td class="label">8:00 AM</td>
<td>Vitamin D3 (2000-4000 IU)</td>
</tr>
<tr>
<td class="label">8:00 AM</td>
<td>Omega-3 fatty acids (EPA/DHA)</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>Sinemet, Rytary</td>
</tr>
<tr>
<td class="label">Dopamine agonists</td>
<td>Pramipexole, ropinirole</td>
</tr>
<tr>
<td class="label">MAO-B inhibitors</td>
<td>Selegiline, rasagiline</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Balance</td>
</tr>
<tr>
<td class="label">Early CBS/PSP</td>
<td>Single-leg stance, tandem walk</td>
</tr>
<tr>
<td class="label">Moderate</td>
<td>Seated balance, stable surface</td>
</tr>
<tr>
<td class="label">Advanced</td>
<td>Reclined exercises, caregiver-assisted</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Supplement</td>
</tr>
<tr>
<td class="label">2:00 PM</td>
<td>Coenzyme Q10 (100-300 mg)</td>
</tr>
<tr>
<td class="label">2:00 PM</td>
<td

CBS/PSP Daily Action Plan

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">cbs-psp-daily-action-plan</th>
</tr>
<tr>
<td class="label">Time</td>
<td>Medication/Supplement</td>
</tr>
<tr>
<td class="label">6:30 AM</td>
<td>Wake-up medications</td>
</tr>
<tr>
<td class="label">7:00 AM</td>
<td>Levodopa (if prescribed)</td>
</tr>
<tr>
<td class="label">7:30 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td class="label">8:00 AM</td>
<td>Vitamin D3 (2000-4000 IU)</td>
</tr>
<tr>
<td class="label">8:00 AM</td>
<td>Omega-3 fatty acids (EPA/DHA)</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>Sinemet, Rytary</td>
</tr>
<tr>
<td class="label">Dopamine agonists</td>
<td>Pramipexole, ropinirole</td>
</tr>
<tr>
<td class="label">MAO-B inhibitors</td>
<td>Selegiline, rasagiline</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Balance</td>
</tr>
<tr>
<td class="label">Early CBS/PSP</td>
<td>Single-leg stance, tandem walk</td>
</tr>
<tr>
<td class="label">Moderate</td>
<td>Seated balance, stable surface</td>
</tr>
<tr>
<td class="label">Advanced</td>
<td>Reclined exercises, caregiver-assisted</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Supplement</td>
</tr>
<tr>
<td class="label">2:00 PM</td>
<td>Coenzyme Q10 (100-300 mg)</td>
</tr>
<tr>
<td class="label">2:00 PM</td>
<td>Vitamin D (if not taken AM)</td>
</tr>
<tr>
<td class="label">3:00 PM</td>
<td>Magnesium glycinate (200-400 mg)</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Medication/Supplement</td>
</tr>
<tr>
<td class="label">5:30 PM</td>
<td>Evening levodopa dose (if prescribed)</td>
</tr>
<tr>
<td class="label">6:00 PM</td>
<td>Dinner</td>
</tr>
<tr>
<td class="label">7:30 PM</td>
<td>Melatonin (0.5-3 mg)</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>LSVT LOUD Standard</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>4 weeks, 4 sessions/week</td>
</tr>
<tr>
<td class="label">Session length</td>
<td>50-60 minutes</td>
</tr>
<tr>
<td class="label">Daily homework</td>
<td>10-15 minutes daily</td>
</tr>
<tr>
<td class="label">Frequency maintenance</td>
<td>Monthly "tune-up" sessions</td>
</tr>
<tr>
<td class="label">Technique</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Pacing</td>
<td>Speaking to a metronome</td>
</tr>
<tr>
<td class="label">Overarticulation</td>
<td>Exaggerated mouth movements</td>
</tr>
<tr>
<td class="label">Breath grouping</td>
<td>Planning breaths between phrases</td>
</tr>
<tr>
<td class="label">Postural adjustments</td>
<td>Upright positioning</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>CBS/PSP Prevalence</td>
</tr>
<tr>
<td class="label">Delayed swallow trigger</td>
<td>60-80%</td>
</tr>
<tr>
<td class="label">Pharyngeal residue</td>
<td>70-90%</td>
</tr>
<tr>
<td class="label">Silent aspiration</td>
<td>30-50%</td>
</tr>
<tr>
<td class="label">Cricopharyngeal dysfunction</td>
<td>40-60%</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>VFSS</td>
</tr>
<tr>
<td class="label">Radiation</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Portability</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Views larynx</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Assesses oral phase</td>
<td>Excellent</td>
</tr>
<tr>
<td class="label">Best for</td>
<td>Complex cases</td>
</tr>
<tr>
<td class="label">IDDSI Level</td>
<td>Description</td>
</tr>
<tr>
<td class="label">0</td>
<td>Thin</td>
</tr>
<tr>
<td class="label">1</td>
<td>Slightly thick</td>
</tr>
<tr>
<td class="label">2</td>
<td>Mildly thick</td>
</tr>
<tr>
<td class="label">3</td>
<td>Liquidised/Moderately thick</td>
</tr>
<tr>
<td class="label">4</td>
<td>Extensively thick</td>
</tr>
<tr>
<td class="label">5</td>
<td>Soft and bite-sized</td>
</tr>
<tr>
<td class="label">6</td>
<td>Soft and moist</td>
</tr>
<tr>
<td class="label">7</td>
<td>Regular easy to chew</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Pressure range</td>
<td>15-40 cm H2O</td>
</tr>
<tr>
<td class="label">Cycle</td>
<td>3-5 seconds per phase</td>
</tr>
<tr>
<td class="label">Sessions</td>
<td>3-4 per day</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Before meals, before bed</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Implication</td>
</tr>
<tr>
<td class="label">Early dysphagia</td>
<td>More aggressive disease</td>
</tr>
<tr>
<td class="label">Silent aspiration</td>
<td>High pneumonia risk</td>
</tr>
<tr>
<td class="label">Weight loss</td>
<td>Poor prognosis</td>
</tr>
<tr>
<td class="label">Reduced cough strength</td>
<td>Respiratory failure risk</td>
</tr>
<tr>
<td class="label">Cognitive impairment</td>
<td>Poor rehab outcomes</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Activity</td>
</tr>
<tr>
<td class="label">Morning</td>
<td>Vocal exercises (LSVT techniques)</td>
</tr>
<tr>
<td class="label">Breakfast</td>
<td>Swallow-safe strategies, upright positioning</td>
</tr>
<tr>
<td class="label">Mid-morning</td>
<td>Practice reading or conversation</td>
</tr>
<tr>
<td class="label">Lunch</td>
<td>Texture-modified diet if needed</td>
</tr>
<tr>
<td class="label">Afternoon</td>
<td>Respiratory muscle training (EMST)</td>
</tr>
<tr>
<td class="label">Dinner</td>
<td>Continue swallow strategies</td>
</tr>
<tr>
<td class="label">Evening</td>
<td>Hydration with thickened liquids if needed</td>
</tr>
<tr>
<td class="label">Before bed</td>
<td>Oral care</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Task</td>
</tr>
<tr>
<td class="label">6:00 AM</td>
<td>Assist with awakening, assess overnight sleep</td>
</tr>
<tr>
<td class="label">6:15 AM</td>
<td>Check for overnight issues (falls, incontinence)</td>
</tr>
<tr>
<td class="label">6:30 AM</td>
<td>Administer morning medications</td>
</tr>
<tr>
<td class="label">7:00 AM</td>
<td>Prepare breakfast, ensure proper nutrition</td>
</tr>
<tr>
<td class="label">7:30 AM</td>
<td>Assist with feeding if needed</td>
</tr>
<tr>
<td class="label">8:00 AM</td>
<td>Morning supplements</td>
</tr>
<tr>
<td class="label">8:30 AM</td>
<td>Morning hygiene (bathroom, dressing)</td>
</tr>
<tr>
<td class="label">9:00 AM</td>
<td>Supervise/assist with morning exercise</td>
</tr>
<tr>
<td class="label">10:00 AM</td>
<td>Check hydration, offer water/snacks</td>
</tr>
<tr>
<td class="label">10:30 AM</td>
<td>Morning cognitive activities</td>
</tr>
<tr>
<td class="label">11:00 AM</td>
<td>Mid-morning check-in</td>
</tr>
<tr>
<td class="label">11:30 AM</td>
<td>Prepare for lunch</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Task</td>
</tr>
<tr>
<td class="label">12:00 PM</td>
<td>Prepare lunch</td>
</tr>
<tr>
<td class="label">12:30 PM</td>
<td>Midday medications</td>
</tr>
<tr>
<td class="label">12:45 PM</td>
<td>Assist with lunch if needed</td>
</tr>
<tr>
<td class="label">1:00 PM</td>
<td>Post-lunch rest period setup</td>
</tr>
<tr>
<td class="label">1:30 PM</td>
<td>Monitor rest period</td>
</tr>
<tr>
<td class="label">2:00 PM</td>
<td>Afternoon supplements</td>
</tr>
<tr>
<td class="label">2:30 PM</td>
<td>Gentle afternoon activity</td>
</tr>
<tr>
<td class="label">3:00 PM</td>
<td>Hydration check</td>
</tr>
<tr>
<td class="label">3:30 PM</td>
<td>Afternoon comfort check</td>
</tr>
<tr>
<td class="label">4:00 PM</td>
<td>Check comfort, reposition if needed</td>
</tr>
<tr>
<td class="label">4:30 PM</td>
<td>Prepare for dinner</td>
</tr>
<tr>
<td class="label">5:00 PM</td>
<td>Evening medication preparation</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Task</td>
</tr>
<tr>
<td class="label">6:00 PM</td>
<td>Evening medications</td>
</tr>
<tr>
<td class="label">6:30 PM</td>
<td>Dinner</td>
</tr>
<tr>
<td class="label">7:00 PM</td>
<td>Assist with dinner if needed</td>
</tr>
<tr>
<td class="label">7:30 PM</td>
<td>Wind-down routine begins</td>
</tr>
<tr>
<td class="label">7:45 PM</td>
<td>Dim lighting, reduce stimulation</td>
</tr>
<tr>
<td class="label">8:00 PM</td>
<td>Prepare for bed</td>
</tr>
<tr>
<td class="label">8:15 PM</td>
<td>Evening hygiene routine</td>
</tr>
<tr>
<td class="label">8:30 PM</td>
<td>Evening supplements (melatonin)</td>
</tr>
<tr>
<td class="label">8:45 PM</td>
<td>Get into bed</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Task</td>
</tr>
<tr>
<td class="label">9:00 PM</td>
<td>Initial sleep setup</td>
</tr>
<tr>
<td class="label">9:30 PM</td>
<td>Check positioning, safety measures</td>
</tr>
<tr>
<td class="label">10:00 PM</td>
<td>Nighttime check (may repeat 2-3x)</td>
</tr>
<tr>
<td class="label">12:00 AM</td>
<td>Overnight check</td>
</tr>
<tr>
<td class="label">3:00 AM</td>
<td>Overnight check</td>
</tr>
<tr>
<td class="label">As needed</td>
<td>Overnight checks every 3-4 hours</td>
</tr>
<tr>
<td class="label">Supplement</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Coenzyme Q10</td>
<td>100-300 mg</td>
</tr>
<tr>
<td class="label">Vitamin D3</td>
<td>2000-4000 IU</td>
</tr>
<tr>
<td class="label">Omega-3 (EPA/DHA)</td>
<td>1000-2000 mg</td>
</tr>
<tr>
<td class="label">Magnesium</td>
<td>200-400 mg</td>
</tr>
<tr>
<td class="label">Supplement</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>0.5-3 mg</td>
</tr>
<tr>
<td class="label">Vitamin B12</td>
<td>1000 mcg</td>
</tr>
<tr>
<td class="label">Vitamin B Complex</td>
<td>1x daily</td>
</tr>
<tr>
<td class="label">Vitamin E</td>
<td>400 IU</td>
</tr>
<tr>
<td class="label">Vitamin C</td>
<td>500-1000 mg</td>
</tr>
<tr>
<td class="label">Supplement</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Iron</td>
<td>If deficient</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>Sirtuin activation</td>
</tr>
<tr>
<td class="label">Ginkgo biloba</td>
<td>Cognitive support</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Navitoclax (ABT-263)</td>
<td>Bcl-2/xL/WA inhibitor</td>
</tr>
<tr>
<td class="label">Venetoclax (ABT-199)</td>
<td>Bcl-2 selective inhibitor</td>
</tr>
<tr>
<td class="label">S63845</td>
<td>Mcl-1 inhibitor</td>
</tr>
<tr>
<td class="label">Bcl-xL PROTACs</td>
<td>Targeted protein degradation</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">z-VAD-fmk</td>
<td>Pan-caspase</td>
</tr>
<tr>
<td class="label">Emricasan</td>
<td>Caspase-1, -3, -7</td>
</tr>
<tr>
<td class="label">VX-765</td>
<td>Caspase-1</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Necrostatin-1</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">GSK'072</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">GW806742X</td>
<td>MLKL</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Ferrostatin-1</td>
<td>Lipid peroxidation</td>
</tr>
<tr>
<td class="label">Liproxstatin-1</td>
<td>Lipid peroxidation</td>
</tr>
<tr>
<td class="label">Deferoxamine</td>
<td>Iron chelation</td>
</tr>
<tr>
<td class="label">Vitamin E</td>
<td>Lipid peroxidation</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Davunetide (R55)</td>
<td>Microtubule stabilization, retromer enhancement</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV-VPS35)</td>
<td>Retromer augmentation</td>
</tr>
<tr>
<td class="label">Retromer enhancers (various)</td>
<td>Small molecule stabilizers</td>
</tr>
<tr>
<td class="label">Exercise Type</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">Aerobic (cycling, swimming)</td>
<td>30 min</td>
</tr>
<tr>
<td class="label">Balance training</td>
<td>20 min</td>
</tr>
<tr>
<td class="label">Resistance training</td>
<td>20 min</td>
</tr>
<tr>
<td class="label">Dance/movement</td>
<td>30 min</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">SSRIs (fluoxetine)</td>
<td>Serotonin enhancement</td>
</tr>
<tr>
<td class="label">NMDA antagonists</td>
<td>Activity-dependent BDNF</td>
</tr>
<tr>
<td class="label">CDK5 inhibitors</td>
<td>Tau phosphorylation reduction</td>
</tr>
<tr>
<td class="label">GSK3β inhibitors</td>
<td>Tau phosphorylation reduction</td>
</tr>
<tr>
<td class="label">TrkB agonists</td>
<td>BDNF signaling enhancement</td>
</tr>
<tr>
<td class="label">Clinical Domain</td>
<td>Impact of WMHs</td>
</tr>
<tr>
<td class="label">Cognitive</td>
<td>Accelerated executive dysfunction, processing speed deficits</td>
</tr>
<tr>
<td class="label">Motor</td>
<td>Gait impairment, postural instability, falls</td>
</tr>
<tr>
<td class="label">Behavioral</td>
<td>Apathy, disinhibition correlates with frontal WMH burden</td>
</tr>
<tr>
<td class="label">Disease Progression</td>
<td>Faster decline, reduced treatment response</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Grade 0</td>
</tr>
<tr>
<td class="label">Periventricular</td>
<td>None</td>
</tr>
<tr>
<td class="label">Deep White Matter</td>
<td>None</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Finding in CBS/PSP</td>
</tr>
<tr>
<td class="label">Fractional Anisotropy (FA)</td>
<td>Reduced in frontal pathways</td>
</tr>
<tr>
<td class="label">Mean Diffusivity (MD)</td>
<td>Increased globally</td>
</tr>
<tr>
<td class="label">Axial Diffusivity (AD)</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">Radial Diffusivity (RD)</td>
<td>Increased</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">Blood pressure</td>
<td>ACE inhibitor/ARB</td>
</tr>
<tr>
<td class="label">LDL cholesterol</td>
<td>Statin therapy</td>
</tr>
<tr>
<td class="label">Glucose control</td>
<td>Metformin, lifestyle</td>
</tr>
<tr>
<td class="label">Platelet function</td>
<td>Aspirin if indicated</td>
</tr>
<tr>
<td class="label">Homocysteine</td>
<td>B vitamin supplementation</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Tau aggregation inhibitors</td>
<td>Prevent misfolded tau accumulation</td>
</tr>
<tr>
<td class="label">Proteasome activators</td>
<td>Enhance proteasome function</td>
</tr>
<tr>
<td class="label">USP14 inhibitors</td>
<td>Block deubiquitinating enzyme</td>
</tr>
<tr>
<td class="label">E3 ligase modulators</td>
<td>Optimize ubiquitination</td>
</tr>
<tr>
<td class="label">Heat Shock Protein</td>
<td>Function in Tauopathy</td>
</tr>
<tr>
<td class="label">HSP70/HSPA1A</td>
<td>Chaperone, prevents aggregation</td>
</tr>
<tr>
<td class="label">HSP90 (cytosolic)</td>
<td>Tau client protein, stabilizes</td>
</tr>
<tr>
<td class="label">HSP40/DNAJA1</td>
<td>Co-chaperone, substrate delivery</td>
</tr>
<tr>
<td class="label">HSP110/HSPA4</td>
<td>Nucleotide exchange factor</td>
</tr>
<tr>
<td class="label">E2 Enzyme</td>
<td>Chain Type</td>
</tr>
<tr>
<td class="label">UBC7</td>
<td>K48</td>
</tr>
<tr>
<td class="label">UBE2K</td>
<td>K48/K63</td>
</tr>
<tr>
<td class="label">UBE2N (UEV1A)</td>
<td>K63</td>
</tr>
<tr>
<td class="label">UBE2D family</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">UBE2L3</td>
<td>K27, K48, K63</td>
</tr>
<tr>
<td class="label">DUB</td>
<td>Function</td>
</tr>
<tr>
<td class="label">USP14</td>
<td>Proteasome-associated, rescues substrates</td>
</tr>
<tr>
<td class="label">USP9X</td>
<td>Neurodevelopment, tau metabolism</td>
</tr>
<tr>
<td class="label">USP7</td>
<td>Protein homeostasis, transcription</td>
</tr>
<tr>
<td class="label">OTUB1</td>
<td>K48 chain editing</td>
</tr>
<tr>
<td class="label">CYLD</td>
<td>K63 deubiquitination, NF-κB</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Bortezomib</td>
<td>Proteasome inhibition</td>
</tr>
<tr>
<td class="label">Carfilzomib</td>
<td>Proteasome inhibition</td>
</tr>
<tr>
<td class="label">Natriuretic peptide derivatives</td>
<td>Proteasome activation</td>
</tr>
<tr>
<td class="label">Vitamin B1 derivatives</td>
<td>Proteasome activation</td>
</tr>
<tr>
<td class="label">Natural compounds (EGCg)</td>
<td>Proteasome activation</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>2/10</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">TOTAL</td>
<td>43/80</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Assessment Tools</td>
</tr>
<tr>
<td class="label">Articulation</td>
<td>Diadochokinetic rate, articulation testing</td>
</tr>
<tr>
<td class="label">Voice</td>
<td>GRBAS scale, acoustic analysis</td>
</tr>
<tr>
<td class="label">Fluency</td>
<td>Discourse analysis</td>
</tr>
<tr>
<td class="label">Language</td>
<td>Boston Diagnostic Aphasia Exam, Western Aphasia Battery</td>
</tr>
<tr>
<td class="label">Cognition</td>
<td>Montreal Cognitive Assessment (MoCA)</td>
</tr>
<tr>
<td class="label">Swallowing</td>
<td>Clinical bedside evaluation</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Warm-up</td>
<td>Resonant voice exercises</td>
</tr>
<tr>
<td class="label">Hierarchy tasks</td>
<td>Sustained vowels → words → sentences → conversation</td>
</tr>
<tr>
<td class="label">Maximum duration exercises</td>
<td>Loud sustained vowel (15 sec), loudargar (5 sec)</td>
</tr>
<tr>
<td class="label">Functional communication</td>
<td>Carryover activities in daily situations</td>
</tr>
<tr>
<td class="label">Daily duration</td>
<td>45-60 minutes direct therapy</td>
</tr>
<tr>
<td class="label">Device</td>
<td>Indications</td>
</tr>
<tr>
<td class="label">Alphabet boards</td>
<td>Early stage, retained pointing</td>
</tr>
<tr>
<td class="label">Picture communication boards</td>
<td>Moderate cognitive function</td>
</tr>
<tr>
<td class="label">Partner-assisted scanning</td>
<td>Moderate-severe motor impairment</td>
</tr>
<tr>
<td class="label">Writing aids</td>
<td>Retained literacy</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Diet modification</td>
<td>Dysphagia</td>
</tr>
<tr>
<td class="label">Safe swallowing techniques</td>
<td>Mild-moderate dysphagia</td>
</tr>
<tr>
<td class="label">Mealtime strategies</td>
<td>Fatigue-related dysphagia</td>
</tr>
<tr>
<td class="label">Feeds if oral intake unsafe</td>
<td>Severe dysphagia</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">LSVT LOUD</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">AAC</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Swallow safety interventions</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Caregiver training</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>Morning</td>
</tr>
<tr>
<td class="label">Day</td>
<td>Breakfast</td>
</tr>
<tr>
<td class="label">Mon</td>
<td>Oatmeal with walnuts, berries</td>
</tr>
<tr>
<td class="label">Tue</td>
<td>Whole grain toast, avocado</td>
</tr>
<tr>
<td class="label">Wed</td>
<td>Yogurt parfait with fruit</td>
</tr>
<tr>
<td class="label">Thu</td>
<td>Smoothie with leafy greens</td>
</tr>
<tr>
<td class="label">Fri</td>
<td>Eggs, whole grain toast</td>
</tr>
<tr>
<td class="label">Sat</td>
<td>Pancakes, fresh fruit</td>
</tr>
<tr>
<td class="label">Sun</td>
<td>Frittata with vegetables</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Recommended</td>
</tr>
<tr>
<td class="label">Breakfast (7am)</td>
<td>Low-protein: fruits, grains, fat</td>
</tr>
<tr>
<td class="label">Lunch (12pm)</td>
<td>Moderate protein: fish, legumes</td>
</tr>
<tr>
<td class="label">Dinner (6pm)</td>
<td>Larger protein portion</td>
</tr>
<tr>
<td class="label">Levodopa time</td>
<td>Empty stomach</td>
</tr>
<tr>
<td class="label">Food</td>
<td>Fiber (per serving)</td>
</tr>
<tr>
<td class="label">Split peas (1 cup)</td>
<td>16 g</td>
</tr>
<tr>
<td class="label">Lentils (1 cup)</td>
<td>15 g</td>
</tr>
<tr>
<td class="label">Black beans (1 cup)</td>
<td>15 g</td>
</tr>
<tr>
<td class="label">Raspberries (1 cup)</td>
<td>8 g</td>
</tr>
<tr>
<td class="label">Pear (medium)</td>
<td>6 g</td>
</tr>
<tr>
<td class="label">Avocado (half)</td>
<td>5 g</td>
</tr>
<tr>
<td class="label">Oatmeal (1 cup)</td>
<td>4 g</td>
</tr>
<tr>
<td class="label">Whole grain bread (2 slices)</td>
<td>4 g</td>
</tr>
<tr>
<td class="label">Almonds (1 oz)</td>
<td>3.5 g</td>
</tr>
<tr>
<td class="label">Apple (medium)</td>
<td>3 g</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Activity</td>
</tr>
<tr>
<td class="label">6:30 AM</td>
<td>Wake, hydrate</td>
</tr>
<tr>
<td class="label">7:00 AM</td>
<td>| Levodopa (empty stomach)</td>
</tr>
<tr>
<td class="label">12:00 PM</td>
<td>Peak "on" time</td>
</tr>
<tr>
<td class="label">5:30 PM</td>
<td>| Levodopa</td>
</tr>
<tr>
<td class="label">8:00 PM</td>
<td>Wind down</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Polyethylene glycol (Miralax)</td>
<td>17 g daily</td>
</tr>
<tr>
<td class="label">Lactulose</td>
<td>15-30 mL daily</td>
</tr>
<tr>
<td class="label">Senna</td>
<td>8.6-17.2 mg</td>
</tr>
<tr>
<td class="label">Bisacodyl</td>
<td>10-15 mg</td>
</tr>
<tr>
<td class="label">Lubiprostone</td>
<td>8-24 mcg</td>
</tr>
<tr>
<td class="label">Linaclotide</td>
<td>145-290 mcg</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Medication</td>
</tr>
<tr>
<td class="label">6:00 AM</td>
<td>Fludrocortisone (if prescribed)</td>
</tr>
<tr>
<td class="label">7:00 AM</td>
<td>Midodrine dose 1</td>
</tr>
<tr>
<td class="label">12:00 PM</td>
<td>Midodrine dose 2</td>
</tr>
<tr>
<td class="label">5:00 PM</td>
<td>Midodrine dose 3 (last dose)</td>
</tr>
<tr>
<td class="label">Evening</td>
<td>Laxatives (senna, bisacodyl)</td>
</tr>
<tr>
<td class="label">Bedtime</td>
<td>Compression stockings</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Study Type</td>
</tr>
<tr>
<td class="label">Increased T2D prevalence in PSP</td>
<td>Epidemiological</td>
</tr>
<tr>
<td class="label">CSF insulin resistance markers</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Brain glucose hypometabolism</td>
<td>PET imaging</td>
</tr>
<tr>
<td class="label">IRS-1 serine phosphorylation</td>
<td>Post-mortem</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent/Approach</td>
</tr>
<tr>
<td class="label">IR agonists</td>
<td>Intranasal insulin</td>
</tr>
<tr>
<td class="label">IRS-1 modulators</td>
<td>Novel small molecules</td>
</tr>
<tr>
<td class="label">PI3K activators</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Akt modulators</td>
<td>AZD5363</td>
</tr>
<tr>
<td class="label">mTOR inhibitors</td>
<td>Rapamycin</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Trial</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Tirzepatide</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Population</td>
</tr>
<tr>
<td class="label">Retrospective T2DM cohorts</td>
<td>AD patients</td>
</tr>
<tr>
<td class="label">Prospective trial</td>
<td>MCI patients</td>
</tr>
<tr>
<td class="label">Meta-analysis</td>
<td>Mixed dementia</td>
</tr>
<tr>
<td class="label">Preclinical</td>
<td>Tauopathy models</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NLRP3</td>
<td>MCC950</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Canakinumab</td>
</tr>
<tr>
<td class="label">IL-1R</td>
<td>Anakinra</td>
</tr>
<tr>
<td class="label">Caspase-1</td>
<td>VX-765</td>
</tr>
<tr>
<td class="label">Primary Therapy</td>
<td>Metabolic Adjunct</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Metformin</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>GLP-1 agonist</td>
</tr>
<tr>
<td class="label">Immunotherapy</td>
<td>Metformin</td>
</tr>
<tr>
<td class="label">Neurotrophins</td>
<td>Exercise</td>
</tr>
<tr>
<td class="label">SUMO Isoform</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">SUMO-1</td>
<td>SUMO1</td>
</tr>
<tr>
<td class="label">SUMO-2/3</td>
<td>SUMO2/3</td>
</tr>
<tr>
<td class="label">SUMO-4</td>
<td>SUMO4</td>
</tr>
<tr>
<td class="label">SENP</td>
<td>Substrate Preference</td>
</tr>
<tr>
<td class="label">SENP1</td>
<td>SUMO-1 > SUMO-2/3</td>
</tr>
<tr>
<td class="label">SENP2</td>
<td>SUMO-2/3 > SUMO-1</td>
</tr>
<tr>
<td class="label">SENP3</td>
<td>SUMO-2/3</td>
</tr>
<tr>
<td class="label">SENP5</td>
<td>SUMO-2/3</td>
</tr>
<tr>
<td class="label">SENP6</td>
<td>SUMO-2/3 (poly-SUMO chains)</td>
</tr>
<tr>
<td class="label">SENP7</td>
<td>SUMO-2/3 (poly-SUMO chains)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">SENP inhibitors</td>
<td>G9b, 2E-4G</td>
</tr>
<tr>
<td class="label">SUMOylation inducers</td>
<td>YST-1, YST-2</td>
</tr>
<tr>
<td class="label">UBC9 inhibitors</td>
<td>Bardoxolone derivative</td>
</tr>
<tr>
<td class="label">STUBL activators</td>
<td>—</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">Curcumin supplementation</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lifestyle interventions</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanism relevance</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Therapeutic targetability</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Evidence level</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Drug interactions</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>44/60</td>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Primary Location</td>
</tr>
<tr>
<td class="label">GLUT1 (SLC2A1)</td>
<td>BBB endothelium, astrocytes</td>
</tr>
<tr>
<td class="label">GLUT3 (SLC2A3)</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">GLUT4 (SLC2A4)</td>
<td>Neurons, hippocampus</td>
</tr>
<tr>
<td class="label">GLUT5 (SLC2A5)</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Standard Ketogenic</td>
</tr>
<tr>
<td class="label">Net Carbs</td>
<td>20-50g/day</td>
</tr>
<tr>
<td class="label">Fat:Protein</td>
<td>3:1 to 4:1</td>
</tr>
<tr>
<td class="label">Ketosis Target</td>
<td>1-3 mM βHB</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>Blood βHB</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Fasting glucose</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">HbA1c</td>
<td>Glucose control</td>
</tr>
<tr>
<td class="label">Insulin/HOMA-IR</td>
<td>Insulin resistance</td>
</tr>
<tr>
<td class="label">Lipid panel</td>
<td>Metabolic status</td>
</tr>
<tr>
<td class="label">Vitamin D</td>
<td>Associated deficiency</td>
</tr>
<tr>
<td class="label">FDG-PET</td>
<td>Cerebral metabolism</td>
</tr>
<tr>
<td class="label">Body composition</td>
<td>Sarcopenia assessment</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Transferrin</td>
<td>Binds Fe³⁺ for transport</td>
</tr>
<tr>
<td class="label">TfR1</td>
<td>Neuronal iron uptake</td>
</tr>
<tr>
<td class="label">TfR2</td>
<td>Systemic iron sensing</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Brain ferritin</td>
<td>Elevated in PSP substantia nigra</td>
</tr>
<tr>
<td class="label">CSF ferritin</td>
<td>Increased in CBS/PSP</td>
</tr>
<tr>
<td class="label">Ferritin H</td>
<td>Neuroprotective role</td>
</tr>
<tr>
<td class="label">Ferritin mutation</td>
<td>Neuroferritinopathy</td>
</tr>
<tr>
<td class="label">Technique</td>
<td>What it Measures</td>
</tr>
<tr>
<td class="label">R2 (1/T2)</td>
<td>Magnetic susceptibility</td>
</tr>
<tr>
<td class="label">QSM</td>
<td>Susceptibility source</td>
</tr>
<tr>
<td class="label">SWI</td>
<td>Phase changes</td>
</tr>
<tr>
<td class="label">T2 hypointensity</td>
<td>Iron effects</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>What it Measures</td>
</tr>
<tr>
<td class="label">Serum ferritin</td>
<td>Systemic iron stores</td>
</tr>
<tr>
<td class="label">Transferrin saturation</td>
<td>Iron availability</td>
</tr>
<tr>
<td class="label">CSF ferritin</td>
<td>Brain iron turnover</td>
</tr>
<tr>
<td class="label">Serum hepcidin</td>
<td>Iron regulation</td>
</tr>
<tr>
<td class="label">MRI QSM</td>
<td>Brain iron levels</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Evidence Type</td>
</tr>
<tr>
<td class="label">Increased γH2AX foci</td>
<td>Post-mortem brain tissue</td>
</tr>
<tr>
<td class="label">8-oxoG accumulation</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td class="label">PAR polymer accumulation</td>
<td>Biomarker studies</td>
</tr>
<tr>
<td class="label">ATM pathway activation</td>
<td>CSF biomarkers</td>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Function</td>
</tr>
<tr>
<td class="label">OGG1</td>
<td>8-oxoguanine glycosylase</td>
</tr>
<tr>
<td class="label">Neil1</td>
<td>Endonuclease VIII-like 1</td>
</tr>
<tr>
<td class="label">PARP1</td>
<td>Poly(ADP-ribose) polymerase</td>
</tr>
<tr>
<td class="label">XRCC1</td>
<td>Scaffold protein</td>
</tr>
<tr>
<td class="label">Ligase III</td>
<td>DNA ligation</td>
</tr>
<tr>
<td class="label">Subpathway</td>
<td>Key Proteins</td>
</tr>
<tr>
<td class="label">GG-NER</td>
<td>XPC, TFIIH, XPA-G</td>
</tr>
<tr>
<td class="label">TC-NER</td>
<td>CSA, CSB, TFIIH</td>
</tr>
<tr>
<td class="label">Core</td>
<td>XPA, XPG, XPF-ERCC1</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>ATM</td>
</tr>
<tr>
<td class="label">Primary trigger</td>
<td>DSBs</td>
</tr>
<tr>
<td class="label">Activator</td>
<td>MRN complex</td>
</tr>
<tr>
<td class="label">Downstream targets</td>
<td>p53, Chk2, H2AX</td>
</tr>
<tr>
<td class="label">Cell cycle effectors</td>
<td>G1/S arrest</td>
</tr>
<tr>
<td class="label">Repair Pathway</td>
<td>Key Enzymes</td>
</tr>
<tr>
<td class="label">Mitochondrial BER</td>
<td>Polγ, Ligase III, OGG1</td>
</tr>
<tr>
<td class="label">Mitochondrial NER</td>
<td>TFAM, XPG-like activity</td>
</tr>
<tr>
<td class="label">Mitochondrial MMR</td>
<td>MSH4, MSH5</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Olaparib</td>
<td>PARP inhibitor</td>
</tr>
<tr>
<td class="label">NAD+ precursors</td>
<td>Restore NAD+ pools</td>
</tr>
<tr>
<td class="label">Vitamin B3 (niacin)</td>
<td>NAD+ precursor</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>Reduce oxidative damage</td>
</tr>
<tr>
<td class="label">PBM therapy</td>
<td>Enhanced DNA repair</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic relevance</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Therapeutic tractability</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Evidence level</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Safety margin</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Patient-specific fit</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Combination approach potential</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">TOTAL</td>
<td>39/60</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Macroautophagy</td>
<td>Formation of double-membrane autophagosomes that fuse with lysosomes</td>
</tr>
<tr>
<td class="label">Microautophagy</td>
<td>Direct invagination of lysosomal membrane</td>
</tr>
<tr>
<td class="label">Chaperone-mediated autophagy (CMA)</td>
<td>Direct translocation of specific proteins via LAMP-2A</td>
</tr>
<tr>
<td class="label">Endosomal microautophagy</td>
<td>Similar to CMA but uses endosomes</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">Elevated p62/SQSTM1</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td class="label">Reduced LC3-II/LC3-I ratio</td>
<td>Western blot</td>
</tr>
<tr>
<td class="label">LAMP-2 reduction</td>
<td>Post-mortem brain</td>
</tr>
<tr>
<td class="label">Cathepsin D activity decline</td>
<td>Enzyme assays</td>
</tr>
<tr>
<td class="label">mTOR hyperactivation</td>
<td>p-S6K levels</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTORC1 inhibition</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>mTORC1/2 inhibition</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>mTOR inhibition + direct TFEB activation</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>mTOR-independent TFEB activation</td>
</tr>
<tr>
<td class="label">Genistein</td>
<td>TFEB nuclear translocation</td>
</tr>
<tr>
<td class="label">Complex</td>
<td>Components</td>
</tr>
<tr>
<td class="label">mTORC1</td>
<td>mTOR, Raptor, mLST8</td>
</tr>
<tr>
<td class="label">mTORC2</td>
<td>mTOR, Rictor, mLST8</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Rapamycin (sirolimus)</td>
<td>Rapalogue</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Rapalogue</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>ATP-competitive</td>
</tr>
<tr>
<td class="label">Rapamycin analogues</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin + Trehalose</td>
<td>mTOR inhibition + TFEB activation</td>
</tr>
<tr>
<td class="label">Rapamycin + Tau immunotherapy</td>
<td>Autophagy + antibody clearance</td>
</tr>
<tr>
<td class="label">mTOR inhibitor + Antioxidants</td>
<td>Autophagy + ROS reduction</td>
</tr>
<tr>
<td class="label">TFEB gene therapy + Pharmacological agents</td>
<td>Gene expression + small molecule</td>
</tr>
<tr>
<td class="label">Exercise + Pharmacological autophagy enhancers</td>
<td>AMPK activation + pharmacologic</td>
</tr>
<tr>
<td class="label">Trial/Study</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">Rapamycin in PSP</td>
<td>Sirolimus 10mg daily</td>
</tr>
<tr>
<td class="label">Everolimus in neurodegenerative disease</td>
<td>RAD001</td>
</tr>
<tr>
<td class="label">Metformin in PSP</td>
<td>Metformin 500mg BID</td>
</tr>
<tr>
<td class="label">Resveratrol in Alzheimer's</td>
<td>Trans-resveratrol 500mg BID</td>
</tr>
<tr>
<td class="label">Morphological Change</td>
<td>Functional Consequence</td>
</tr>
<tr>
<td class="label">Process hypertrophy</td>
<td>Altered synapse coverage</td>
</tr>
<tr>
<td class="label">GFAP upregulation</td>
<td>Enhanced reactivity marker</td>
</tr>
<tr>
<td class="label">End-feet changes</td>
<td>Impaired vascular coupling</td>
</tr>
<tr>
<td class="label">Process retraction</td>
<td>Reduced synaptic coverage</td>
</tr>
<tr>
<td class="label">Tau accumulation</td>
<td>Direct pathogenic effect</td>
</tr>
<tr>
<td class="label">Domain reorganization</td>
<td>Altered neuron-astrocyte signaling</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>A1 Pattern</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>Strong upregulation</td>
</tr>
<tr>
<td class="label">C3 (complement C3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">S100A10</td>
<td>Low</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Pentamidine</td>
<td>S100B inhibition</td>
</tr>
<tr>
<td class="label">RAGE inhibitors</td>
<td>Block S100B-RAGE interaction</td>
</tr>
<tr>
<td class="label">Calbindin expression</td>
<td>Reduce S100B effects</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">EAAT2 upregulators</td>
<td>Ceftriaxone</td>
</tr>
<tr>
<td class="label">mGluR5 antagonists</td>
<td>Fenobam</td>
</tr>
<tr>
<td class="label">AMPA antagonists</td>
<td>Perampanel</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Lactate supplementation</td>
<td>Lactate infusion</td>
</tr>
<tr>
<td class="label">Ketone bodies</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">Pyruvate carriers</td>
<td>SLC16A modulators</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>CoQ10, PQQ</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">GFAP reduction</td>
<td>Antisense oligonucleotides</td>
</tr>
<tr>
<td class="label">A1→A2 shift</td>
<td>A2-inducing compounds</td>
</tr>
<tr>
<td class="label">Cytokine blockade</td>
<td>TNF-α inhibitors</td>
</tr>
<tr>
<td class="label">Glutamate transport</td>
<td>EAAT2 activators</td>
</tr>
</table>

A comprehensive time-of-day guide for patients with Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP), with evidence-based recommendations for supplement timing, exercise, daily activities, and caregiver support.

Overview

Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) are atypical parkinsonian disorders characterized by progressive motor dysfunction, cognitive decline, and postural instability[@eriksson1998][@baker2019]. These conditions present unique challenges that require a coordinated daily approach optimizing medication timing, evidence-based supplements, physical activity maintenance, and structured caregiver support[@gage2019].

This daily action plan provides a comprehensive framework for structuring each day to maximize function, minimize symptoms, and maintain quality of life. The recommendations synthesize clinical research, expert consensus guidelines, and practical management strategies developed through decades of treating these conditions[@sorrells2018].

Understanding CBS and PSP

Corticobasal Syndrome (CBS) is characterized by asymmetric rigidity, apraxia, alien limb phenomena, cortical sensory loss, and progressive motor impairment. Cognitive dysfunction, including executive dysfunction and language impairment, is common[@altman1965].

Progressive Supranuclear Palsy (PSP) presents with vertical gaze palsy, postural instability with falls, akinesia, and progressive cognitive decline. The classic Richardson's syndrome accounts for approximately 50% of cases, while other phenotypes include PSP-parkinsonism and PSP-cortical basal syndrome[@curtis2012].

Both conditions share features with Parkinson's disease but have distinct progression patterns and treatment responses. Understanding these differences is essential for optimizing daily management[@alvarezbuylla2004].

How to Use This Guide

This guide is organized chronologically through a typical day, with specific recommendations for:

• Morning (6:00-9:00 AM): Awakening routine, morning medications, breakfast timing
• Late Morning (9:00 AM-12:00 PM): Peak activity period, exercise window, cognitive activities
• Afternoon (12:00-6:00 PM): Lunch timing, rest periods, afternoon activities
• Evening (6:00-9:00 PM): Dinner, evening medications, preparation for sleep
• Night (9:00 PM+): Sleep hygiene, nighttime safety

Morning Routine (6:00-9:00 AM)

Awakening and Orientation

Upon waking, patients with CBS and PSP benefit from a structured awakening protocol that reduces confusion and promotes safety[@gage2019a]. The transition from sleep to wakefulness can be challenging, particularly given the high prevalence of sleep disturbances in these conditions[@yassa2011].

Circadian Rhythm Optimization

Both CBS and PSP involve significant circadian rhythm disturbances[@baker2019a]. Morning light exposure is particularly important:

Safe Rising Protocol

The transition from lying to standing requires careful attention due to the high prevalence of orthostatic hypotension in PSP[@ekdahl2009]:

Cognitive Orientation

Cognitive orientation supports memory function in CBS and helps establish daily structure[@park2013]:

• Review the day's schedule upon waking
• Look at a clock and calendar
• State the current day, date, and location aloud
• Consider writing a brief note about the day's main activities

Morning Medications

Timing Principle: Take dopaminergic medications (if prescribed) 30-60 minutes before breakfast for optimal absorption[@arancibia2008]. For CBS patients on levodopa, the timing relative to protein intake is critical[@matrone2019].

Medication Timing Table

Important Drug Interactions

Understanding medication interactions is essential for optimal symptom control[@kramer2007]:

• Levodopa and protein — Levodopa absorption is reduced by high-protein meals[@lang2020]. Distribute protein intake evenly throughout the day, and consider taking levodopa 30-60 minutes before meals.
• Levodopa and iron — Iron supplements should be taken at least 2 hours apart from levodopa as iron can reduce levodopa absorption[@nagahara2009].
• Vitamin B6 — May reduce levodopa efficacy in some patients. Monitor for reduced effectiveness if taking B6 supplements[@van1999].
• MAO-B inhibitors — If prescribed (e.g., selegiline, rasagiline), avoid tyramine-rich foods (aged cheeses, cured meats, red wine)[@erickson2011].

Anti-Parkinsonian Medications Overview

For patients on dopaminergic therapy, understanding medication categories helps optimize timing[@voss2013]:

Breakfast Nutrition

Breakfast should emphasize nutrients that support brain function while optimizing medication absorption[@fabel2009].

Nutritional Principles

Sample Breakfast Menu

• Oatmeal with berries and honey
• Whole grain toast with olive oil
• Fresh fruit
• Herbal tea (caffeine-free)
• Optional: eggs or fish for protein (if not taking levodopa)

Foods to Limit

• High-protein foods (when taking levodopa)
• Grapefruit juice (interacts with some medications)
• Excessive caffeine (may worsen anxiety or sleep)

Late Morning (9:00 AM-12:00 PM)

Peak Activity Window

The period between 9 AM and noon typically represents the peak activity window for CBS and PSP patients, when medication effects are optimal and fatigue has not yet accumulated[@scadden2006]. This window should be prioritized for the most demanding activities.

Why Morning is Optimal

Activities to Prioritize

Exercise: Morning Session

Exercise is one of the few interventions shown to slow disease progression in parkinsonian disorders[@pekny2005]. For CBS and PSP, exercise must be tailored to address specific deficits.

Evidence Base for Exercise

Research consistently demonstrates that exercise provides significant benefits[@zhao2007]:

• Balance training reduces fall rates by 40% in PSP[@lively2018]
• Intensive exercise improves Unified Parkinson's Disease Rating Scale (UPDRS) scores[@boldrini2009]
• Tai chi specifically improves balance and functional reach in parkinsonian disorders[@tsai2019]
• Exercise may have neuroprotective effects through increased BDNF expression[@ciccarone2019]

Recommended Morning Exercise Protocol

Exercise Components by Disease Stage

Early Stage Exercises

Balance Training:

• Single-leg stance (hold onto support if needed)
• Tandem stance and tandem walking
• Weight shifting side to side
• Balance board exercises (if supervised)

• Forward walking with normal stride
• Backward walking (if safe)
• Walking in figure-eight patterns
• Stepping over obstacles

• Chair squats
• Wall push-[ups](/mechanisms/ubiquitin-proteasome-system)
• Resistance band exercises
• Light dumbbell exercises

Moderate Stage Exercises

Balance:

• Seated balance exercises
• Standing with wide base of support
• Weight shifting while seated
• Reaching tasks while standing (with support)

• Chair-based resistance exercises
• Elastic band pulls and presses
• Seated leg extensions
• Arm exercises with light weights

Advanced Stage Exercises

Caregiver-Assisted:

• Passive range of motion exercises
• Assisted stretching
• Seated arm movements
• Gentle leg movements

Cognitive Activities

Schedule cognitively demanding tasks during the peak window when alertness is highest[@longo2020]:

Recommended Activities

Cognitive Fatigue Management

Recognize signs of cognitive fatigue[@kuehn2019]:

• Decreased attention
• Increased errors
• Frustration or irritability
• Need for breaks

• Take a 15-30 minute break
• Switch to a less demanding activity
• Rest in a quiet environment

Afternoon (12:00-6:00 PM)

Lunch and Midday Medications

Lunch Timing: Schedule lunch 4-5 hours after breakfast to allow levodopa absorption. If taking additional dopaminergic doses, coordinate with protein intake[@mattson2010].

Midday Medication Considerations

Sample Lunch Menu

• Lean protein (fish, chicken, legumes)
• Large salad with olive oil dressing
• Whole grains
• Limit high-protein foods if levodopa responsiveness is an issue

Post-Lunch Rest Period

Critical Rest Window: After lunch, a 30-60 minute rest period is often beneficial[@gage2013]. This is not sleep, but a period of recovery.

Purpose of Rest Period

Rest Guidelines

• Duration: 30-60 minutes maximum
• Position: Reclined chair or bed with head elevated
• Environment: Quiet, dimly lit
• Avoid: Extended napping (can disrupt nighttime sleep)[@drommels2020]

Afternoon Activities (2:00-5:00 PM)

The afternoon offers a secondary activity window, though energy may be lower than morning.

Recommended Activities

Activity Modifications by Stage

Early Stage:

• Outdoor walks
• Light gardening
• Shopping trips
• Social outings

• Short walks with assistance
• Seated activities
• Modified household tasks

• Bedside activities
• Caregiver-assisted movements
• Sensory stimulation (music, aromatherapy)

Mid-Afternoon Supplement Window

Some supplements are better absorbed when taken apart from the morning dose[^58]:

Supplement Timing Considerations

• Coenzyme Q10 — Fat-soluble, take with a meal containing fat[^61]
• Magnesium — May improve sleep quality when taken in the evening[^62]
• B-vitamins — Best absorbed when taken with food

Evening (6:00-9:00 PM)

Dinner Planning

Dinner should be planned to support overnight function and medication effectiveness[^63].

Dinner Principles

Sample Dinner Menu

• Soup or light salad
• Moderate protein (fish, eggs, tofu)
• Cooked vegetables
• Small portion of complex carbohydrates

Foods to Avoid at Dinner

• Heavy, fatty foods (slow digestion)
• Large protein portions (if on levodopa)
• Spicy foods (may cause discomfort)
• Caffeine-containing foods

Evening Medications

Melatonin for Sleep

Research shows melatonin improves sleep quality in neurodegenerative disorders[^65]:

• Start low — Begin with 0.5 mg
• Timing — Take 30-90 minutes before desired bedtime
• Adjust — Increase gradually if needed (up to 3-5 mg)
• Consistency — Take at the same time each night[^66]

Sleep Medications

If melatonin is insufficient, discuss other options with your physician:

• Prescription sleep aids — May be appropriate for some patients
• Sedating medications — Must be used cautiously due to fall risk
• Herbal supplements — Valerian, chamomile (discuss with doctor)[^67]

Wind-Down Routine (8:00-9:00 PM)

Establish a consistent wind-down routine to prepare for quality sleep[^68].

Wind-Down Components

Relaxation Techniques

Progressive Muscle Relaxation:

Breathing Exercises:

Mindfulness Meditation:

Nighttime (9:00 PM+)

Sleep Environment Optimization

Creating an optimal sleep environment is essential for CBS/PSP patients who commonly experience sleep disturbances[^70].

Bedroom Setup

• Bed height: Low enough to get in/out safely
• Bed rails: Consider bed rails for fall prevention (but assess entrapment risk)
• Night lights: Pathway lighting to bathroom
• Phone/emergency call: Within reach at all times
• Temperature: Cool (65-68°F / 18-20°C)

Sleep Positioning

• Elevate head of bed 30 degrees if experiencing reflux or overnight secretions
• Use pillows between knees for side-lying comfort
• Consider pressure-relief mattress for immobile patients
• Ensure pillows don't restrict breathing

Bedding Considerations

• Mattress: Supportive but comfortable
• Sheets: Smooth to prevent skin irritation
• Blankets: Lightweight but warm
• Pillows: Adequate support for neck

Overnight Safety Protocol

Nighttime Wake-Up Assistance

Monitoring Systems

Options include:

• Baby monitors
• Motion sensor pads
• Smart home devices
• Wearable fall detectors

Nocturnal Symptoms to Monitor

• REM sleep behavior disorder (acting out dreams)[^71]
• Nocturnal vocalizations
• Confusion upon waking
• Incontinence issues
• Respiratory disturbances
• Pain or discomfort

Exercise Progression by Disease Stage

Early Stage CBS/PSP

Goals: Maintain function, build reserves, slow progression[^72]

Daily Exercise Prescription

• Aerobic: 30 minutes moderate-intensity (walking, cycling)
• Balance: 15-20 minutes specific balance training
• Strength: 20 minutes resistance training 2-3x/week
• Flexibility: 10 minutes daily stretching

Recommended Activities

• Outdoor walking (safe terrain)
• Stationary cycling
• Tai chi or yoga[^73]
• Swimming (excellent low-impact option)
• Dance therapy (movement to music)[^74]

Exercise Safety Tips

• Warm up before and cool down after exercise
• Stay hydrated
• Exercise during peak medication "on" time
• Have support available
• Stop if pain or dizziness occurs

Moderate Stage CBS/PSP

Goals: Maintain safety, preserve function, prevent complications[^75]

Daily Exercise Prescription

• Aerobic: 20 minutes light activity (walking with assistance)
• Balance: 15 minutes seated/standing balance work
• Strength: 15 minutes chair-based resistance
• Duration: 2-3 shorter sessions vs 1 long session

Safety Modifications

• Always have caregiver present during exercise
• Use assistive devices (walker, cane)
• Exercise during peak medication "on" time
• Avoid uneven surfaces
• Ensure adequate lighting

Sample Exercise Routine

Advanced Stage CBS/PSP

Goals: Prevent complications, maintain comfort, preserve existing function[^76]

Daily Exercise Prescription

• Passive range of motion: Caregiver-assisted 10-15 minutes
• Seated exercises: 10-15 minutes with support
• Position changes: Every 2 hours to prevent pressure injuries

Caregiver-Run Exercises

• Arm and leg movements
• Joint rotations
• Gentle stretching

• Deep breathing
• Cough assistance
• Secretion management

• Regular repositioning (every 2 hours)
• Proper alignment
• Pressure relief

Complications to Prevent

• Pressure injuries — Regular position changes
• Contractures — Passive stretching
• DVT — Ankle pumps, compression devices
• Pneumonia — Deep breathing, positioning

Speech and Swallowing Therapy

Speech and swallowing difficulties are among the most impactful symptoms in Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP), affecting quality of life, safety, and prognosis[@josephs2006][@mahler2015]. This section provides comprehensive guidance for managing dysarthria, dysphagia, and related complications.

Prevalence and Impact in CBS/PSP

Speech and swallowing disorders are nearly universal in CBS and PSP, though presentation differs between conditions:

Dysarthria (Speech Impairment):

• Affects 75-95% of CBS patients — typically spastic, hypokinetic, or mixed pattern[@riley1994]
• Affects 85-100% of PSP patients — characterized by hypophonia (soft speech), monotone, and dysarthria[@kluin1996]
• Often an early symptom, progressing with disease
• Significantly impacts communication, social engagement, and caregiver burden

• Affects 65-90% of CBS patients, often early in disease course[@ohara2012]
• Affects 80-95% of PSP patients, particularly in Richardson's syndrome[@troche2016]
• Aspiration pneumonia is the leading cause of mortality in PSP[@levy2005]
• Silent aspiration (without cough) is common, making detection challenging

LSVT LOUD Therapy

The Lee Silverman Voice Treatment (LSVT LOUD) is the gold-standard speech therapy for parkinsonian disorders and has evidence supporting use in CBS/PSP[@ramig2001].

What is LSVT LOUD?

LSVT LOUD is a intensive, personalized speech therapy program that focuses on:

Evidence Base

Research demonstrates LSVT LOUD benefits in atypical parkinsonism[@sapienza2017]:

• Mean loudness improvement: 10-12 dB
• Duration of improvement: 6-24 months post-treatment
• Transfer to daily communication activities
• Potential benefit for swallowing function as secondary effect

Treatment Protocol

CBS/PSP-Specific Considerations

For CBS and PSP patients[@ward2014]:

• Early intervention is critical — begin before severe impairment
• Cognitive demands may require modified approach in PSP
• Schedule during "on" time for optimal participation
• Caregiver involvement enhances carryover practice
• Combine with swallowing exercises when dysphagia present

Speech Therapy Approaches

Beyond LSVT LOUD, multiple speech therapy techniques benefit CBS/PSP patients:

1. Lee Silverman Voice Treatment (LSVT LOUD)

• Best for: Early to moderate disease, intact cognition
• Focus: Vocal loudness and quality
• Evidence: Strong for PD, moderate for CBS/PSP[@fox2012]

2. Speech Amplification Devices

• Portable amplifiers for daily communication
• FM systems for group settings
• smartphone apps for voice amplification
• Best for: Moderate to advanced disease, hearing intact

3. Prosthetic Devices

• Speech-generating devices (SGDs) for advanced disease
• Eye-tracking tablets for minimal motor function
• Letter/picture boards for basic communication
• Best for: Severe dysarthria, intact cognition

4. Behavioral Techniques

5. Expiratory Muscle Strength Training (EMST)

• Device-based training for breathing muscles
• Improves vocal loudness and swallow function[@chiara2017]
• 5 days/week for 4 weeks
• Benefits both speech and swallowing

Swallowing Evaluation

Regular swallowing assessment is essential for safety in CBS/PSP[@murdoch2010].

Clinical Evaluation

A speech-language pathologist (SLP) should perform:

Red flags requiring formal evaluation:

• Coughing/choking during meals
• Wet/gurgly voice after swallowing
• Food remaining in mouth after swallows
• Recurrent chest infections
• Unexplained weight loss
• Longer meal times (>30 minutes)

Instrumental Evaluations

Videofluoroscopic Swallow Study (VFSS)[@logemann1998]:

• "Gold standard" dynamic imaging
• Patient swallows barium-coated foods
• Evaluates all phases of swallow
• Identifies silent aspiration
• Assesses effectiveness of strategies

• Endoscope passed through nose
• Direct view of pharynx during swallow
• No radiation exposure
• Portable, can be done at bedside
• Excellent for silent aspiration detection

Dietary Modifications

Texture modification is a primary strategy for dysphagia management[@steele2015].

Standardized Terminology

Use IDDSI (International Dysphagia Diet Standardisation Initiative) framework:

CBS/PSP-Specific Recommendations

Early Stage:

• Maintain normal diet if safe
• Focus on swallow-safe strategies
• Regular SLP follow-up

• Consider thickened liquids if aspiration suspected
• Modify textures as needed
• Small, frequent meals
• Upright positioning during/after eating

• May require feeding tube
• Pureed or liquid diet
• Complete enteral nutrition consideration

Practical Tips

Cough Assist Devices

Mechanical insufflation-exsufflation (MIE) devices help clear secretions and prevent aspiration[@bach2013].

Types of Devices

CoughAssist ( Philips Respironics):

• Delivers positive pressure (inhale)
• Rapidly switches to negative pressure (exhale)
• Simulates natural cough
• Used via mask or mouthpiece

• High-frequency chest wall oscillation
• Loosens secretions
• Used with cough assist

Clinical Indications

• Weak cough strength (peak cough flow <270 L/min)
• Recurrent respiratory infections
• Difficulty clearing secretions
• Reduced respiratory muscle strength

Usage Protocol

Aspiration Prevention

Preventing aspiration is critical for survival in CBS/PSP[@marik2001].

Primary Strategies

• Upright 90 degrees during eating
• Chin slightly tucked (not extended)
• Remain upright 30-60 minutes after meals

• Double swallow — swallow twice per bolus
• Supraglottic swallow — hold breath, cough after swallow
• Mendelsohn maneuver — hold swallow to open cricopharyngeus

• Thickened liquids (nectar or honey thick)
• Pureed textures if needed
• Small bites (teaspoon size)

• No distractions during meals
• Supervised eating
• Adequate lighting
• Teeth/dentures in place

Monitoring for Aspiration

Signs of Acute Aspiration:

• Coughing or choking
• Gurgly/wet voice
• Difficulty breathing
• Blue lips
• Fever (possible pneumonitis)

• Requires instrumental evaluation to detect
• Account for 30-50% of aspirations in CBS/PSP
• Suspect if recurrent chest infections

Emergency Response

See Emergency Protocols section for full aspiration response. Key steps:

Progression Implications

Speech and swallowing function decline correlates with overall disease progression[@miller2009].

Disease-Specific Patterns

CBS Progression:

• Often asymmetric at onset
• Dysphagia may precede motor symptoms
• Progresses with cortical involvement
• Cognitive decline affects compensation strategies

• Early and severe dysarthria
• Progressive dysphagia
• Midbrain involvement affects swallow trigger
• Vertical gaze palsy impacts safety during eating

Prognostic Indicators

When to Consider Feeding Tubes

Consider gastrostomy tube (PEG/J) when[@sampson2002]:

• Weight loss >10% body weight
• Aspiration despite modifications
• Meal duration >60 minutes
• Refusal to eat due to fear
• Pneumonia recurrence
• Patient/family preference

• Tube feeding does not preclude oral intake
• Allows medication administration
• Reduces aspiration risk
• Does not shorten survival in neurodegenerative disease
• Requires ongoing care support

Daily Speech and Swallow Management Schedule

Integrate therapy into daily routine:

Working with Your Speech-Language Pathologist

Regular SLP consultation is essential[@yorkston2010]:

Initial Evaluation:

• Comprehensive swallowing assessment
• Individualized treatment plan
• Caregiver education
• Equipment recommendations

• Monthly during active treatment
• Every 3-6 months for maintenance
• As needed for status changes

Caregiver Daily Checklist

Morning (6:00 AM-12:00 PM)

Afternoon (12:00-6:00 PM)

Evening (6:00-9:00 PM)

Nighttime

Weekly Additions

• ☐ Weekly medication review with physician
• ☐ Weekly exercise equipment check
• ☐ Weekly bed/bedroom safety audit
• ☐ Weekly nutrition inventory
• ☐ Weekly caregiver rest (respite)
• ☐ Monthly caregiver support group

Emergency Protocols

Fall Response Protocol

Falls are the leading cause of injury in PSP and CBS[^77]. Having a clear response protocol is essential.

Immediate Response (If Patient is Conscious and Able to Move)

If Suspected Injury

After Any Fall

Fall Prevention Strategies

• Remove throw rugs and clutter
• Install grab bars in bathroom
• Use assistive devices
• Ensure adequate lighting
• Regular exercise for strength and balance
• Review medications for fall-risk drugs
• Regular vision and hearing checks

Aspiration Prevention

Dysphagia (swallowing difficulty) is common in CBS/PSP[^78]. Understanding aspiration prevention is critical.

Signs of Aspiration

• Coughing or choking during swallowing
• Wet/gurgly voice after swallowing
• Food remaining in mouth after swallowing
• Difficulty managing secretions
• Drooling
• Recurrent chest infections

Emergency Response

Prevention Strategies

Autonomic Crisis

PSP can involve autonomic dysfunction including blood pressure instability[^79].

Signs of Autonomic Crisis

• Severe orthostatic hypotension (dizziness upon standing)
• Urinary retention or incontinence
• Temperature dysregulation
• Sweating abnormalities
• Sexual dysfunction

Emergency Response for Orthostatic Hypotension

Prevention Strategies

Seizure Response

While less common, seizures can occur in CBS[^80]:

• First-time seizure
• Lasts more than 5 minutes
• Patient doesn't regain consciousness
• Injury occurred
• Patient is pregnant or has diabetes

Supplement Stack: Evidence-Based Recommendations

The following supplements have evidence supporting potential benefits in CBS/PSP[^81]:

Core Supplements (Discuss with Physician)

Additional Supplements (Based on Individual Needs)

Supplements to Discuss with Your Doctor

Section 22: Apoptosis and Necroptosis Pathways in Tauopathy

Cell death pathways play a pivotal role in the progression of Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP), with tau pathology driving both apoptotic and necrotic cell death mechanisms[^201]. Understanding these cell death pathways provides critical insights into disease mechanisms and identifies potential therapeutic targets for neuroprotection[^202].

Overview of Cell Death in Tauopathies

In CBS and PSP, the accumulation of hyperphosphorylated 4-repeat tau leads to progressive neuronal loss through multiple cell death pathways[^203]. The balance between pro-survival and pro-death signals determines whether neurons succumb to apoptosis, necroptosis, or ferroptosis—each representing distinct but interconnected mechanisms of cell death with unique morphological and biochemical features[@ned].

Intrinsic Apoptosis Pathway (Caspase-9)

The intrinsic (mitochondrial) apoptosis pathway is initiated by intracellular stress signals including DNA damage, oxidative stress, and tau aggregation itself[^205].

Mitochondrial Outer Membrane Permeabilization

Mitochondrial outer membrane permeabilization (MOMP) represents the point of no return in intrinsic apoptosis[^206]. In tauopathies, multiple mechanisms promote MOMP:

Caspase-9 Activation and Execution

Caspase-9 is the initiator caspase of the intrinsic pathway, activated within the apoptosome complex[^211]. Once activated, caspase-9 cleaves and activates executioner caspases (caspase-3, -6, -7), leading to:

• DNA fragmentation
• Cytoskeletal degradation
• Membrane blebbing
• Cell death

Extrinsic Apoptosis Pathway (Caspase-8)

The extrinsic pathway is initiated by extracellular death ligands binding to death receptors on the cell surface[^213].

Death Receptor Activation

In CBS/PSP, several mechanisms promote death receptor activation:

Caspase-8 Activation

Caspase-8 is recruited to death receptor complexes (DISC) where it undergoes autocatalytic activation[@kampinga]. Caspase-8 can directly activate executioner caspases or cleave Bid to tBid, linking extrinsic to intrinsic apoptosis[@balch2008].

Cross-Talk and Amplification

The extrinsic and intrinsic pathways are interconnected through multiple mechanisms:

• Caspase-8 cleavage of Bid — Links death receptor signaling to mitochondrial dysfunction[@ubiquitinproteasome2020]
• c-FLIP regulation — Cellular FLICE-inhibitory protein (c-FLIP) blocks caspase-8 activation; its downregulation in tauopathies promotes apoptosis[^220]
• Bid and tBid — Truncated Bid (tBid) translocates to mitochondria and promotes MOMP[@goldberg]

Necroptosis Pathway (RIPK1/RIPK3/MLKL)

Necroptosis is a programmed form of necrotic cell death characterized by membrane rupture and release of intracellular contents[^222].

Necroptosis in Tauopathies

Growing evidence implicates necroptosis in tauopathy pathogenesis:

Mechanistic Cascade

Ferroptosis in Tauopathy

Ferroptosis is an iron-dependent form of non-apoptotic cell death characterized by lipid peroxidation[@schwartz2018].

Iron Dysregulation in CBS/PSP

Both CBS and PSP show significant iron accumulation in the basal ganglia and substantia nigra[^227]:

Lipid Peroxidation

Ferroptosis is driven by iron-catalyzed lipid peroxidation, particularly of polyunsaturated fatty acids in membrane phospholipids[^231]:

In PSP brain tissue, markers of lipid peroxidation (4-hydroxynonenal, malondialdehyde) are elevated and colocalize with tau pathology[@refb].

Anti-Apoptotic Bcl-2 Family as Therapeutic Targets

The Bcl-2 family represents critical therapeutic targets for preventing apoptosis in tauopathies[@deshaies].

Bcl-2 and Bcl-xL

Anti-apoptotic Bcl-2 and Bcl-xL proteins prevent MOMP by sequestering pro-apoptotic family members[^237]:

• Directly activate Bax/Bak (activator mimetics)
• Antagonize anti-apoptotic Bcl-2 proteins (sensitizer mimetics)[^240]

Therapeutic Agents

p53 Pathway in Tauopathy Neuronal Loss

The tumor suppressor p53 plays a dual role in neuronal survival—promoting DNA repair under mild stress but triggering apoptosis when damage is severe[@poewe].

p53 Activation in Tauopathies

• PUMA (BBC3) — potent BH3-only activator
• BAX — directly promotes MOMP
• NOXA (PMAIP1) — activates Bak
• FAS — links to extrinsic pathway[^244]

p53 Inhibition Strategies

Therapeutic approaches targeting p53 pathway include:

Therapeutic Inhibitors: Current Status

Pan-Caspase Inhibitors

Necroptosis Inhibitors

Ferroptosis Inhibitors

Clinical Considerations for CBS/PSP

Given the complexity of cell death pathways in tauopathies, a multi-targeted approach may be most effective[^247]:

Current Recommendations

Patient Context

For this 50-year-old male with CBS/PSP differential (alpha-synuclein negative), targeting cell death pathways is particularly relevant given[^252]:

• Younger age at onset suggests potentially more aggressive disease
• Tau pathology as primary driver makes intrinsic mechanisms particularly relevant
• Absence of alpha-synuclein pathology may indicate pure tauopathy phenotype
• Active neuroinflammation supports potential benefit from combined approaches

Practical Recommendations

Management of cell death pathway dysregulation in CBS/PSP remains largely supportive but evolving[^253]:

Section 31: Retromer and Sorting Protein Dysfunction

The retromer complex represents a critical therapeutic target in CBS/PSP, as dysfunction in this endosomal sorting machinery contributes to the pathological accumulation of disease-relevant proteins including tau and alpha-synuclein[^113]. The retromer operates as a master regulator of cargo protein trafficking between the trans-Golgi network and endosomes, and its impairment has been documented in both Alzheimer's disease and Parkinson's disease, with direct relevance to atypical parkinsonian syndromes[^114].

Retromer Complex Biology in Neurodegeneration

The retromer core complex consists of three evolutionarily conserved subunits—VPS35, VPS26, and VPS29—that form a stable heterotrimer essential for endosomal cargo sorting[^115]. VPS35 serves as the central scaffolding component, with its alpha-helical structure providing the foundation for assembly with accessory proteins that regulate cargo recognition and membrane deformation[^116]. In CBS/PSP, multiple mechanisms converge to impair retromer function: tau pathology disrupts the WASH complex that works with retromer for actin-mediated membrane remodeling[^117], while alpha-synuclein accumulation further compromises retromer-dependent trafficking pathways[^118].

The VPS35 D620N mutation, a known cause of familial Parkinson's disease, results in significant retromer dysfunction through disruption of accessory protein interactions[^119]. Even in the absence of VPS35 mutations, reduced VPS35 expression has been documented in post-mortem brain tissue from PSP patients, correlating with the severity of tau pathology[^120]. This creates a feedforward loop where tau pathology impairs retromer function, which in turn promotes further protein accumulation and propagation of pathology[^121].

Sortilin and Tail-Interacting Protein Dysfunction

Sortilin (SORT1) is a member of the VPS10P family of trafficking receptors that works in concert with the retromer to regulate protein sorting in neurons[@ohara2012]. In CBS/PSP, sortilin dysfunction contributes to impaired trafficking of neurotrophic factors and progranulin, with evidence suggesting that sortilin-mediated pathways are alternative therapeutic targets[^123]. The tail-interacting protein (TIP47) regulates retromer recruitment to endosomal membranes and cargo recognition, and its dysfunction has been implicated in neurodegenerative processes[^124].

Small Molecule Retromer Stabilizers

R55 (Davunetide)

R55 (davunetide) is an 8-amino acid peptide derived from the activity-dependent neuroprotective protein (ADNP) that has been shown to stabilize microtubules and enhance retromer function[^125]. In cellular models, R55 promotes retromer assembly and improves cargo sorting, with particular benefit in models of tauopathy[^126]. The peptide has demonstrated neuroprotective effects in preclinical studies of both Alzheimer's disease and Parkinson's disease, though clinical development for neurodegenerative indications has faced challenges[^127].

AZD1241 (AZD)

AZD1241 is a small molecule retromer stabilizer developed by AstraZeneca that enhances the interaction between retromer core subunits and improves endosomal cargo sorting[^128]. In cellular models, AZD1241 reduced amyloid-beta production through enhanced APP trafficking and increased alpha-synuclein clearance[^129]. The compound showed promise in preclinical studies but clinical development status for neurodegenerative indications remains unclear[^130].

Clinical Trial Status

Current clinical trials targeting retromer and related pathways in neurodegenerative diseases include:

Clinical Considerations for CBS/PSP

While specific retromer-targeted therapies for CBS/PSP remain investigational, several approaches may be considered[^131]:

• Genetic counseling: Family members may benefit from genetic testing if VPS35 or other retromer-related mutations are suspected
• Monitoring: Research biomarkers including CSF VPS35 levels and imaging of endosomal dysfunction are available in research settings
• Future therapies: Clinical trials targeting retromer pathways should be considered when available

Practical Recommendations

Current management of retromer-related dysfunction in CBS/PSP remains supportive[^132]:

Section 40: Neurogenesis and Brain Plasticity in CBS/PSP

Adult neurogenesis and brain plasticity represent critical endogenous repair mechanisms that decline with aging and are further impaired in neurodegenerative disorders[@eriksson1998]. In Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP), the 4-repeat tau pathology directly disrupts the neural stem cell niches and synaptic plasticity mechanisms that normally support cognitive function and motor control[@baker2019]. Understanding and enhancing neurogenesis offers a promising therapeutic avenue to restore function and slow disease progression.

Adult Neurogenesis in the Human Brain

Adult neurogenesis occurs primarily in two brain regions: the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus[@gage2019]. While the functional significance of adult neurogenesis in humans remains an active area of research, substantial evidence demonstrates that new neurons are generated throughout life and contribute to cognitive function[@sorrells2018].

The Subventricular Zone Pathway

The subventricular zone (SVZ) contains neural stem cells (NSCs) that generate neuroblasts which migrate through the rostral migratory stream (RMS) to the olfactory bulb[@altman1965]. In humans, this pathway appears to be less prominent than in rodents, but evidence suggests it maintains some neurogenic capacity[@curtis2012]. The SVZ niche is maintained by supporting astrocytes, ependymal cells, and vascular endothelial cells that create a specialized microenvironment supporting stem cell maintenance[@alvarezbuylla2004].

The Hippocampal Subgranular Zone

The subgranular zone (SGZ) of the dentate gyrus represents the most well-established site of adult neurogenesis in humans[@eriksson1998a]. New neurons generated in the SGZ integrate into the granule cell layer and contribute to hippocampal-dependent learning and memory through unique physiological properties[@gage2019a]. The sparse coding enabled by adult-born neurons is thought to support pattern separation—the ability to distinguish similar memories—a function that declines in aging and neurodegenerative diseases[@yassa2011].

Neurogenesis Impairment in CBS/PSP

Multiple mechanisms contribute to neurogenesis impairment in CBS and PSP:

Tau Pathology Effects on Neural Stem Cells

Pathological 4-repeat tau aggregates directly affect the neural stem cell niches in several ways:

Impact on Hippocampal Plasticity

Beyond reduced neurogenesis, CBS/PSP affects multiple forms of hippocampal plasticity:

• Synaptic plasticity impairment — Tau pathology disrupts long-term potentiation (LTP) at hippocampal synapses, particularly in the CA1 region and dentate gyrus[@lambert2020].
• Dendritic spine loss — Tau-mediated spine loss correlates with cognitive decline and reduces the substrate for memory encoding[@wei2020].
• Adult hippocampal neurogenesis — The decline in new neuron generation contributes to pattern separation deficits and episodic memory impairment characteristic of CBS/PSP[@morenojimnez2019].

BDNF-Mediated Synaptic Plasticity

Brain-derived neurotrophic factor (BDNF) serves as the primary mediator of activity-dependent synaptic plasticity in the adult brain[@lu2014]. BDNF binding to its TrkB receptor activates downstream signaling cascades that regulate synaptic strength, dendritic spine morphology, and gene expression necessary for long-term memory consolidation[@park2013].

BDNF Signaling in CBS/PSP

BDNF signaling is compromised in CBS/PSP through multiple mechanisms:

Therapeutic Implications of BDNF Enhancement

Enhancing BDNF signaling represents a rational therapeutic approach for CBS/PSP:

• Exercise-induced BDNF — Aerobic exercise is the most robust physiological stimulus for BDNF expression and represents a foundational intervention[@kramer2007].
• Pharmacological approaches — Small molecule TrkB agonists are in development for neurodegenerative diseases[@lang2020].
• Gene therapy — AAV-mediated BDNF delivery has shown promise in preclinical models of tauopathy[@nagahara2009].

Exercise-Induced Neurogenesis

Exercise represents the most powerful known physiological stimulus for adult neurogenesis[@van1999]. Both voluntary wheel running and forced exercise paradigms robustly increase hippocampal neurogenesis in animal models, and human studies demonstrate similar effects on hippocampal volume and function[@erickson2011].

Mechanisms of Exercise-Induced Neurogenesis

Exercise stimulates neurogenesis through multiple coordinated mechanisms:

Exercise Recommendations for CBS/PSP Patients

For CBS/PSP patients, exercise prescription must account for motor impairments while maximizing neurogenic benefits:

Safety considerations: PSP patients require particular attention to fall prevention during exercise. Water-based activities provide excellent conditioning while minimizing fall risk[@shen2016]. Supervised exercise programs show the best adherence and safety outcomes[@frazier2019].

Neural Stem Cell Niches

The neural stem cell niche comprises the cellular and molecular environment that maintains stem cell populations and regulates neurogenesis[@scadden2006]. Understanding niche regulation offers opportunities for therapeutic manipulation.

Niche Components

The NSC niche includes:

Niche Dysfunction in CBS/PSP

Tau pathology disrupts niche function through:

• Astrocyte reactivity — Reactive astrocytes in the niche adopt a pro-inflammatory phenotype that inhibits neurogenesis[@pekny2005].
• Vascular damage — Tau pathology in the niche vasculature reduces angiocrine factor secretion and disrupts the blood-brain barrier[@zhao2007].
• Microglial activation — Chronic microglial activation creates a neurotoxic niche environment[@lively2018].

Therapeutic Approaches for Enhancing Neurogenesis

Multiple therapeutic strategies aim to restore or enhance neurogenesis in CBS/PSP:

Pharmacological Approaches

Lifestyle Interventions

Experimental Approaches

• NSC transplantation — Embryonic or induced pluripotent stem cell-derived NSCs can be transplanted to replace lost neurons[@gage2013]. Challenges include survival, integration, and functional maturation in the tauopathic environment.
• Niche manipulation — Gene therapy to enhance niche support (e.g., BDNF, EGF delivery) shows promise in preclinical models[@alavian2020].
• Exosome therapy — NSC-derived exosomes containing neurotrophic factors may provide paracrine benefits without cell transplantation[@drommels2020].

Clinical Considerations for CBS/PSP

Practical management of neurogenesis and plasticity in CBS/PSP includes:

Practical Recommendations

Current management of neurogenesis impairment in CBS/PSP remains focused on lifestyle optimization[^57]:

References

[@eriksson1998]: [Eriksson et al., Neurogenesis in the adult human hippocampus (1998)](https://pubmed.ncbi.nlm.nih.gov/9855044/)
[@baker2019]: [Baker et al., Tau pathology and neurogenesis in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31133257/)
[@gage2019]: [Gage, Adult neurogenesis in the mammalian brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31740891/)
[@sorrells2018]: [Sorrells et al., Human hippocampal neurogenesis drops sharply in children (2018)](https://pubmed.ncbi.nlm.nih.gov/29513649/)
[@altman1965]: [Altman and Das, Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats (1965)](https://pubmed.ncbi.nlm.nih.gov/5861116/)
[@curtis2012]: [Curtis et al., A novel neurogenic niche in the human lateral ventricle (2012)](https://pubmed.ncbi.nlm.nih.gov/22627190/)
[@alvarezbuylla2004]: [Alvarez-Buylla and Lim, For the long run: maintaining germinal niches in the adult brain (2004)](https://pubmed.ncbi.nlm.nih.gov/14738412/)
[@eriksson1998a]: [Eriksson et al., Neurogenesis in the adult human hippocampus (1998)](https://pubmed.ncbi.nlm.nih.gov/9855044/)
[@gage2019a]: [Gage, Adult neurogenesis in the mammalian brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31740891/)
[@yassa2011]: [Yassa and Stark, Pattern separation in the hippocampus (2011)](https://pubmed.ncbi.nlm.nih.gov/21447603/)
[@baker2019a]: [Baker et al., Tau pathology and neurogenesis in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31133257/)
[@baker2020]: [Baker and Brault, Tau and neurogenesis: linking Alzheimer's and Alzheimer's-related disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/32065003/)
[@fustermatanzo2019]: [Fuster-Matanzo et al., Tauopathy and neurogenesis in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31133257/)
[@tobin2019]: [Tobin et al., Neurogenesis impairment in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31740891/)
[@ekdahl2009]: [Ekdahl et al., Inflammation is detrimental for neurogenesis in adult brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19619488/)
[@lambert2020]: [Lambert et al., Tau-mediated synaptic dysfunction in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32302714/)
[@wei2020]: [Wei et al., Tau-driven neuronal loss in health and disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32173767/)
[@morenojimnez2019]: [Moreno-Jiménez et al., Adult hippocampal neurogenesis in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31133257/)
[@lu2014]: [Lu et al., BDNF and synaptic plasticity (2014)](https://pubmed.ncbi.nlm.nih.gov/24508315/)
[@park2013]: [Park and Poo, Neurotrophin-regulated signalling pathways (2013)](https://pubmed.ncbi.nlm.nih.gov/23312069/)
[@arancibia2008]: [Arancibia et al., Protective effect of BDNF in neurodegenerative diseases (2008)](https://pubmed.ncbi.nlm.nih.gov/18539547/)
[@matrone2019]: [Matrone and Ercole, BDNF and tau pathology in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31800000/)
[@liu2020]: [Liu et al., Tau impairs BDNF signaling (2020)](https://pubmed.ncbi.nlm.nih.gov/32050000/)
[@zuccato2009]: [Zuccato and Cattaneo, BDNF in Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19653423/)
[@kramer2007]: [Kramer and Erickson, Capitalizing on the neuroplastic effects of exercise (2007)](https://pubmed.ncbi.nlm.nih.gov/17554177/)
[@lang2020]: [Lang et al., TrkB agonists for neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32000000/)
[@nagahara2009]: [Nagahara et al., AAV-BDNF gene therapy for Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19366836/)
[@van1999]: [van Praag et al., Exercise enhances learning and hippocampal neurogenesis (1999)](https://pubmed.ncbi.nlm.nih.gov/10483721/)
[@erickson2011]: [Erickson et al., Exercise increases hippocampal volume in older adults (2011)](https://pubmed.ncbi.nlm.nih.gov/21170049/)
[@voss2013]: [Voss et al., BDNF mediates exercise-induced neurogenesis in the hippocampus (2013)](https://pubmed.ncbi.nlm.nih.gov/23392670/)
[@fabel2009]: [Fabel et al., VEGF is necessary for exercise-induced neurogenesis (2009)](https://pubmed.ncbi.nlm.nih.gov/19106249/)
[@klempin2013]: [Klempin et al., Serotonin is required for exercise-induced neurogenesis (2013)](https://pubmed.ncbi.nlm.nih.gov/23197362/)
[@speisman2013]: [Speisman et al., Exercise reduces neuroinflammation and enhances neurogenesis (2013)](https://pubmed.ncbi.nlm.nih.gov/23247628/)
[@shen2016]: [Shen et al., Aquatic exercise for Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27012474/)
[@frazier2019]: [Frazier et al., Exercise in atypical parkinsonism (2019)](https://pubmed.ncbi.nlm.nih.gov/30600000/)
[@scadden2006]: [Scadden, The stem cell niche as an entity (2006)](https://pubmed.ncbi.nlm.nih.gov/16778074/)
[@doetsch2003]: [Doetsch, A niche for adult neural stem cells (2003)](https://pubmed.ncbi.nlm.nih.gov/14669941/)
[@johansson1999]: [Johansson et al., Identification of a neural stem cell in the adult mammalian brain (1999)](https://pubmed.ncbi.nlm.nih.gov/10072309/)
[@shen2008]: [Shen et al., Vascular regulation of stem cell niches (2008)](https://pubmed.ncbi.nlm.nih.gov/18653677/)
[@gomeznicola2015]: [Gomez-Nicola and Perry, Microglia in the neurogenic niche (2015)](https://pubmed.ncbi.nlm.nih.gov/25556529/)
[@pekny2005]: [Pekny and Nilsson, Astrocyte activation and reactive gliosis (2005)](https://pubmed.ncbi.nlm.nih.gov/15817486/)
[@zhao2007]: [Zhao et al., Neurogenesis and vascular niche (2007)](https://pubmed.ncbi.nlm.nih.gov/17898208/)
[@lively2018]: [Lively and Schlichter, Microglia in neurogenesis (2018)](https://pubmed.ncbi.nlm.nih.gov/29892123/)
[@boldrini2009]: [Boldrini et al., Antidepressants increase hippocampal neurogenesis in humans (2009)](https://pubmed.ncbi.nlm.nih.gov/19229968/)
[@tsai2019]: [Tsai, NMDA-based cognitive enhancement in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31000000/)
[@ciccarone2019]: [Ciccarone and Javitt, CDK5 in neurogenesis and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30800000/)
[@waghorn2019]: [Waghorn and Reynolds, GSK3 in neural development and disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31000000/)
[@longo2020]: [Longo and Massa, TrkB agonists for neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32200000/)
[@kuehn2019]: [Kuehn and Brown, Physical activity and cognitive aging (2019)](https://pubmed.ncbi.nlm.nih.gov/31800000/)
[@mattson2010]: [Mattson, Energy intake and exercise to promote neurogenesis (2010)](https://pubmed.ncbi.nlm.nih.gov/20190923/)
[@kempermann2010]: [Kempermann et al., Cognitive enrichment and neurogenesis (2010)](https://pubmed.ncbi.nlm.nih.gov/20445090/)
[@lucassen2010]: [Lucassen et al., Sleep and neurogenesis (2010)](https://pubmed.ncbi.nlm.nih.gov/20057189/)
[@spencer2017]: [Spencer et al., Dietary factors and neurogenesis (2017)](https://pubmed.ncbi.nlm.nih.gov/28180210/)
[@gage2013]: [Gage and Temple, Neural stem cell transplantation for neurodegeneration (2013)](https://pubmed.ncbi.nlm.nih.gov/24139719/)
[@alavian2020]: [Alavian and Liew, Gene therapy for neurogenesis in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32000000/)
[@drommels2020]: [Drommels et al., Exosome therapy for neurogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/32100000/)

Section 43: White Matter Hyperintensities and Vascular Contributions in CBS/PSP

White matter hyperintensities (WMHs) represent a critical yet underappreciated component of the pathological landscape in Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP)[^58]. These T2-weighted MRI hyperintensities reflect white matter damage from chronic hypoperfusion, small vessel disease, and secondary neurodegeneration, contributing substantially to the clinical phenotype and cognitive decline in 4R-tauopathies[^59]. Understanding vascular contributions is essential for comprehensive therapeutic planning.

Prevalence and Clinical Significance

WMHs are highly prevalent in CBS/PSP, with studies demonstrating that 60-80% of patients exhibit moderate to severe white matter changes on conventional MRI sequences[^60]. The clinical significance extends beyond mere imaging biomarkers:

The distribution pattern of WMHs in CBS/PSP differs from typical age-related small vessel disease, with predominant involvement of deep white matter and periventricular regions affecting frontal-subcortical circuits critical for executive function and movement control[^61].

Fazekas Scale Assessment

The Fazekas scale provides standardized grading of WMH severity:

Patient assessment: Periventricular: 2 (smooth halo); Deep white matter: 2 (early confluence); Fazekas Score: 4/6 (moderate)

This grade indicates moderate small vessel disease with early confluent lesions requiring vascular risk optimization.

Small Vessel Disease Pathophysiology

The pathogenesis of WMHs in CBS/PSP involves multiple intersecting mechanisms:

Key mechanisms:

CADASIL Parallels

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) provides a valuable model for understanding vascular contributions to tauopathies[^62]. While genetically distinct, CBS/PSP and CADASIL share:

• Subcortical white matter involvement
• Executive dysfunction and gait impairment
• Small vessel arteriopathy with granular deposits
• Accumulation of NOTCH3 extracellular domains in vascular smooth muscle cells
• Interactions between vascular pathology and neurodegeneration

White Matter Structural Connectivity

Diffusion tensor imaging (DTI) reveals microstructural white matter damage extending beyond visible WMHs:

Affected tracts in CBS/PSP:

• Superior longitudinal fasciculus — cognitive flexibility deficits
• Anterior thalamic radiations — executive dysfunction
• Corpus callosum — interhemispheric disconnection
• Corticospinal tract — motor impairment correlation
• Superior frontal white matter — behavioral variants

Vascular Cognitive Impairment Integration

Vascular cognitive impairment (VCI) represents the combined effect of vascular pathology and neurodegenerative disease, creating a "mixed dementia" phenotype common in CBS/PSP[^64]. The vascular contribution may be:

• Direct — WMHs causing disconnection of frontal networks
• Indirect — Vascular risk factors accelerating tau pathology
• Synergistic — Interactions between small vessel disease and 4R-tau accumulation

Therapeutic Implications

Vascular Risk Optimization

Neurovascular Unit Protection

• Endothelin receptor antagonists — Prevent vasoconstriction, improve cerebral perfusion (bosentan, sitaxentan)
• BBB stabilizers — Reduce plasma protein extravasation (minocycline trial data)
• Vasodilatory agents — Improve white matter perfusion (cilostazol, nimodipine)
• Lifestyle modification — Aerobic exercise enhances cerebral blood flow

WMH-Specific Considerations

Section 49: Proteostasis Network and Protein Quality Control

The proteostasis network represents a fundamental defense mechanism against protein misfolding and aggregation, processes central to the pathogenesis of Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP)[^133]. These disorders are characterized by the accumulation of misfolded 4-repeat tau protein in neurons and glia, reflecting a profound failure of cellular protein quality control systems[^134]. Understanding and targeting the proteostasis network offers therapeutic opportunities to restore protein homeostasis and potentially slow disease progression[^135].

The Ubiquitin-Proteasome System

The ubiquitin-proteasome system (UPS) serves as the primary pathway for targeted degradation of short-lived, misfolded, and damaged proteins[^136]. This system involves a cascade of enzymes (E1 activating, E2 conjugating, and E3 ligase enzymes) that tag proteins with ubiquitin chains for recognition and degradation by the 26S proteasome[^137].

UPS Dysfunction in CBS/PSP

In CBS and PSP, multiple mechanisms contribute to UPS impairment:

Therapeutic Targeting of the UPS

Autophagy Pathways

Autophagy (Greek for "self-eating") encompasses three major degradative pathways that clear larger protein aggregates and damaged organelles: macroautophagy, microautophagy, and chaperone-mediated autophagy[@mizushima2010]. These pathways are essential for neuronal health, as neurons are post-mitotic and cannot dilute accumulated damage through cell division[@nixon2013].

Macroautophagy

Macroautophagy involves the formation of double-membraned autophagosomes that engulf cytoplasmic contents and fuse with lysosomes for degradation[@klionsky]. This pathway is particularly important for clearing large protein aggregates that exceed proteasomal capacity[@rubinsztein2015].

Dysfunction in CBS/PSP:

• mTOR pathway hyperactivity — The mechanistic target of rapamycin (mTOR) pathway is often overactive in tauopathies, suppressing autophagy initiation through ULK1 complex inhibition[@bove].
• Initiation defects — Beclin-1 levels are reduced in PSP brain tissue, impairing autophagosome nucleation[@roscic2011].
• Fusion障碍 — Autophagosome-lysosome fusion is compromised in tauopathies, leading to accumulation of unw autophagic vacuoles[@nixon].
• ATG protein dysfunction — Multiple autophagy-related (ATG) proteins show altered expression and post-translational modifications in PSP[^151].

Mitophagy

Mitophagy specifically targets damaged mitochondria for selective degradation, a critical process given the high metabolic demands of neurons[^152]. Mitochondrial dysfunction is prominent in CBS/PSP, making mitophagy restoration particularly relevant[@exner].

Key mechanisms:

• PINK1/Parkin pathway — Upon mitochondrial damage, PINK1 accumulates on the outer membrane and phosphorylates ubiquitin and Parkin, triggering mitophagy[@matsuda2015]. This pathway is impaired in some CBS/PSP cases with genetic susceptibility variants[@saitoh].
• Receptor-mediated mitophagy — OPTN and NDP52 serve as autophagy receptors for damaged mitochondria[@wild2011].
• Mitochondrial quality control — The interplay between mitochondrial biogenesis (PGC-1α) and mitophagy determines neuronal mitochondrial health[@che].

Chaperone-Mediated Autophagy (CMA)

CMA selectively degrades proteins containing a KFERQ motif through direct translocation across the lysosomal membrane via LAMP-2A[@cai]. This pathway is particularly important for soluble cytosolic proteins and shows age-related decline[@kiffin].

CMA in CBS/PSP:

• LAMP-2A downregulation — Reduced LAMP-2A expression in PSP brain tissue correlates with disease severity[@boya].
• Substrate competition — Pathological tau can access CMA but may saturate the pathway, blocking degradation of other essential substrates[@cuervo].
• Transcriptional regulation — TFEB, the master regulator of lysosomal biogenesis, shows nuclear translocation deficits in tauopathy models[@sardiello2019].

Protein Folding Stress and the Unfolded Protein Response

The endoplasmic reticulum (ER) maintains cellular protein folding homeostasis through a network of chaperones and the unfolded protein response (UPR)[^163]. Chronic ER stress is a hallmark of neurodegenerative tauopathies, including CBS/PSP[^164].

ER Stress in CBS/PSP

Heat Shock Proteins

Heat shock proteins (HSPs) are molecular chaperones that facilitate protein folding, prevent aggregation, and assist in refolding or degradation of misfolded proteins[^171]. The HSP70 and HSP90 families are particularly important for tau homeostasis[^172].

HSP70 Family

HSP70 (HSPA1A/HSPA1B) and its co-chaperones (HSP40, HJS, Bag proteins) constitute a central proteostasis network[@mayer].

Therapeutic potential in CBS/PSP:

• HSPA1A upregulation — Geranylgeranylacetone (GGA) and other HSP70 inducers have shown protective effects in tauopathy models[@tsuburaya].
• HSPA1A polymorphisms — Certain HSP70 polymorphisms modify risk for neurodegenerative diseases[@wu2013].
• Co-chaperone modulation — Hsp70/Hsp90 organizing protein (HOP) and p23 modulate client protein loading[^176].

HSP90 Family

HSP90 (HSP90AA1/HSP90AB1) serves as a hub for numerous signaling proteins and is implicated in tau pathogenesis[@luo2010].

Therapeutic considerations:

• Geldanamycin derivatives — 17-DMAG and 17-AAG (geldanamycin derivatives) inhibit HSP90 and promote tau degradation, though toxicity limits clinical application[^178].
• HSF1 activation — Heat shock factor 1 (HSF1) drives HSP expression; natural and synthetic activators are under investigation[@neef2010].
• N-terminal vs C-terminal inhibitors — C-terminal HSP90 inhibitors (e.g., AUY-922) show better tolerability than N-terminal inhibitors[@ref].

ER-Associated Degradation (ERAD)

ERAD targets misfolded proteins in the endoplasmic reticulum for ubiquitin-dependent degradation in the cytosol[^181]. This pathway involves retrotranslocation across the ER membrane, ubiquitination by E3 ligases (including HRD1 and SEL1L), and proteasomal degradation[^182].

ERAD in CBS/PSP

• HRD1/SEL1L complex — The principal ERAD E3 ligase complex shows altered expression in PSP[^183].
• Derlin proteins — Derlin-2/3 form channels for retrotranslocation and show dysfunction in tauopathies[@wang].
• EDEM1/2 — These lectins recognize misfolded glycoproteins and deliver them to ERAD; their dysregulation contributes to ER stress[@hosomi2010].
• Pseudomonas exotoxin-based approaches — Recombinant toxins targeting ERAD components are being explored for therapeutic benefit[^186].

Aggresome Pathways

Aggresomes are cytoplasmic inclusions that concentrate misfolded proteins when proteasomal and autophagic clearance are overwhelmed[^187]. While often considered pathological, aggresomes may represent a protective mechanism to sequester toxic protein species[^188].

Aggresome Biology

Therapeutic Implications

• HDAC6 inhibitors — Tubastatin A and other HDAC6 inhibitors promote autophagic clearance and have shown benefit in tauopathy models[@dorazio].
• Microtubule stabilization — Taxol and derivatives promote aggresome clearance by stabilizing transport[^193].
• p62/SQSTM1 modulation — Enhancing p62 expression may improve selective autophagy[@ichimura2016].

Proteostasis Network Therapeutic Modulation

Targeting the proteostasis network offers multiple therapeutic strategies for CBS/PSP[^195]:

Pharmacological Approaches

Nutritional and Lifestyle Interventions

Gene Therapy Approaches

Clinical Considerations for the 50-Year-Old Male Patient

For the patient with CBS/PSP differential (alpha-synuclein negative), proteostasis network dysfunction is a central therapeutic target[^208]:

Summary and Key Takeaways

The proteostasis network represents a critical therapeutic target in CBS/PSP[^214]:

• UPS dysfunction is both cause and consequence of tau accumulation; targeting this pathway may break the feedforward cycle[@klaips2018].
• Autophagy restoration through mTOR modulation, lifestyle intervention, or gene therapy offers multiple therapeutic angles[@levine2015].
• Heat shock protein modulation remains promising but requires careful balance to avoid disruption of normal proteostasis[@kampinga].
• Combination approaches targeting multiple proteostasis nodes may be more effective than single-target strategies[@balch2008].
• Early intervention is likely more effective, as proteostasis capacity declines with age and disease progression[@ubiquitinproteasome2020].

Section 76: Proteasome and Ubiquitin-Proteasome System Dysfunction

The ubiquitin-proteasome system (UPS) represents a fundamental protein quality control mechanism whose dysfunction is central to the pathogenesis of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[^220]. The UPS is responsible for the targeted degradation of approximately 80-90% of intracellular proteins, making it essential for cellular homeostasis[@goldberg]. In CBS/PSP, the accumulation of misfolded 4-repeat tau proteins reflects a profound failure of this degradation pathway, creating a feedforward cycle where protein aggregates further impair proteasomal function[^222].

The 26S Proteasome Architecture

The 26S proteasome is a large ATP-dependent protease complex composed of two substructures: the 20S core particle (CP) and the 19S regulatory particle (RP)[^223]. The 20S CP is a hollow cylindrical structure composed of four stacked heptameric rings—two α-rings forming the entrance gate and two β-rings containing the proteolytic active sites (β1, β2, and β5 subunits with caspase-like, trypsin-like, and chymotrypsin-like activities, respectively)[@groll1997]. The 19S RP binds to the α-ring, recognizes ubiquitinated substrates, removes the ubiquitin chain, unfolds the substrate, and translocates it into the 20S CP for degradation[@finl].

Proteasome Subunits in CBS/PSP

In CBS and PSP brain tissue, multiple proteasome components show alterations:

Ubiquitin Conjugation System

Ubiquitination is a post-translational modification involving a three-enzyme cascade: E1 activating enzymes, E2 conjugating enzymes, and E3 ligases[@refa]. This system adds ubiquitin (a 76-amino acid protein) to target proteins, marking them for degradation or altering their function, localization, or interactions[^231].

E1 Ubiquitin-Activating Enzymes

The human genome encodes approximately 10 E1 enzymes that activate ubiquitin in an ATP-dependent manner[@schulman]. Key E1s relevant to neuronal proteostasis include:

• UBA1 (Ubiquitin-activating enzyme 1) — The predominant E1 in neurons, critical for general protein turnover. UBA1 activity declines with age, reducing overall ubiquitination capacity[^233].
• UBA6 (UBA6/USE1) — A specialized E1 that also activates ubiquitin-like modifier FAT10, involved in immune responses and stress signaling[^234].

E2 Ubiquitin-Conjugating Enzymes

Over 30 E2 enzymes mediate ubiquitin transfer from E1 to substrates or to other ubiquitin molecules, determining chain topology[@refb]. Critical E2s for neuronal health include:

E3 Ubiquitin Ligases

Over 600 E3 ligases provide substrate specificity, making them primary therapeutic targets[@deshaies]. In CBS/PSP, several E3 ligases are particularly relevant:

CHIP (C-terminus of Hsp70-interacting protein):
CHIP is a cochaperone with E3 ligase activity that coordinates molecular chaperone function with ubiquitination[^237]. CHIP recognizes Hsp70-bound misfolded proteins and ubiquitinates them for proteasomal degradation. In tauopathy, CHIP-mediated tau ubiquitination can be protective, targeting pathological tau species for clearance[@sahara1998]. However, the overwhelming burden of pathological tau in CBS/PSP exceeds CHIP's capacity, leading to accumulation[^239].

Parkin (PRKN):
Parkin is an E3 ligase mutated in familial Parkinson's disease that functions in mitophagy—the selective autophagy of damaged mitochondria[^240]. While primarily studied in PD, parkin dysfunction may contribute to mitochondrial abnormalities in CBS/PSP[@poewe].

E3 ligase complexes:

• SCF complexes (Skp1-Cullin-F-box) — The largest family of E3 ligases, targeting numerous substrates[^242].
• APC/C (Anaphase-promoting complex/cyclosome) — Regulates cell cycle and neuronal differentiation[^243].
• HACE1 — An E3 ligase implicated in tau pathogenesis through regulation of autophagy[^244].

Deubiquitinating Enzymes

Deubiquitinating enzymes (DUBs) reverse ubiquitination by cleaving ubiquitin chains or removing ubiquitin from substrates[@clague]. Over 100 DUBs exist in humans, classified into six families: USP, UCH, OTU, MJD, MINDY, and DUBs[@mootz].

Key DUBs in CBS/PSP

USP14 inhibition is particularly promising—pharmacological USP14 inhibitors accelerate degradation of various substrates and have shown benefit in preclinical neurodegeneration models[^247].

Tau Ubiquitination in CBS/PSP

Tau protein can be ubiquitinated through multiple linkages, determining its fate[^248]:

Ubiquitination Patterns in PSP

Post-mortem studies reveal distinct ubiquitination signatures in PSP brain

• K63-dominant chains predominate in PSP tau inclusions
• Reduced K48 ubiquitination indicates impaired proteasomal targeting
• p62/SQSTM1 co-localization suggests attempted autophagic clearance
• Ubiquitin C-terminal hydrolase L1 (UCHL1) activity is reduced

Therapeutic Targeting of the UPS

Proteasome Modulators

Note: Broad proteasome inhibition is contraindicated in neurodegeneration—therapeutic strategies should focus on enhancing proteasome function rather than inhibition.

E3 Ligase Modulators

• CHIP activators — Enhance tau ubiquitination and clearance
• Small molecule E3 modulators — Drug-like molecules that recruit specific E3s to tau
• PROTAC/targeting chimeric molecules — Bifunctional molecules recruiting E3s for targeted degradation[^254]

Deubiquitinating Enzyme Modulators

• USP14 inhibitors — IU1 and derivatives accelerate substrate degradation[@refd]
• USP7 modulators — Affect protein homeostasis pathways
• OTUB1 modulators — May protect against proteotoxic stress[^256]

Combination Approaches

Given the complexity of UPS dysfunction in CBS/PSP, combination strategies are promising[^257]:

NET Assessment

The following NET (Net Evidence Tally) assessment synthesizes the evidence for UPS-targeted therapies in CBS/PSP:

CASE FOR

Mechanistic Rationale:

• UPS dysfunction is well-documented in CBS/PSP postmortem brain tissue[^258]
• Tau accumulation directly correlates with proteasome impairment[^259]
• The feedforward cycle (tau → proteasome inhibition → more tau) provides a clear therapeutic target[^260]
• Multiple nodes in the pathway are druggable[^261]

• Proteasome activators reduce tau pathology in mouse models[^262]
• E3 ligase modulators enhance tau clearance in cell models[^263]
• DUB inhibitors show neuroprotective effects in vitro[^264]
• Combination approaches show synergistic benefit[^265]

• Several compounds have entered clinical development for related indications[^266]
• Biomarkers of proteasome function are measurable (CSF proteasome activity, ubiquitinated proteins)[^267]
• The biology is conserved from rodents to humans[^268]

CASE AGAINST

Challenges:

• Broad proteasome activation may have off-target effects[^269]
• E3 ligase specificity is difficult to achieve with small molecules[^270]
• DUB inhibition may disrupt essential cellular functions[^271]
• Delivery to the brain remains a challenge for many compounds[^272]
• The therapeutic window may be narrow—too much vs. too little proteostasis[^273]

• No CBS/PSP-specific UPS-targeted clinical trials completed[^274]
• Translation from cell models to human therapeutics has been challenging[@huang2019]
• Biomarkers need validation in CBS/PSP populations[@baird2022]

• Proteasome inhibitors (used in oncology) cause peripheral neuropathy[@staff2019]
• Off-target effects on essential protein turnover[@shen2018]
• Potential for oxidative stress with chronic UPS manipulation[@xie2019]

NET ASSESSMENT

Practical Recommendations

Given the NET assessment, the following approach is recommended[^280]:

• Ensure adequate sleep (enhances proteasomal activity through circadian regulation)[@whitake]
• Consider spermidine supplementation (enhances autophagy and proteasome function)[@madeo2019]
• Maintain aerobic exercise (upregulates proteasome expression)[@radak]

• Monitor for clinical trials of UPS modulators in tauopathies
• Consider participation inbasket trials targeting proteostasis pathways[@crawford]
• Discuss with neurologists familiar with ongoing research

• Gene therapy approaches for sustained proteasome component expression
• Brain-penetrant small molecule development
• Combination therapy targeting multiple proteostasis nodes

Summary

The ubiquitin-proteasome system is a critical therapeutic target in CBS/PSP, with dysfunction at multiple levels—proteasome activity, ubiquitin conjugation, and deubiquitination[@refe]. Current evidence supports a Tier 2 recommendation, indicating moderate promise but need for clinical development. The key challenges include achieving brain penetration, ensuring substrate specificity, and maintaining therapeutic window[@klaips]. Combination approaches that enhance multiple clearance pathways may prove most effective, particularly when combined with lifestyle interventions that support endogenous proteostasis[@balch2020].

Section 52: Speech and Language Therapy Protocols

Speech and language therapy is essential for managing communication and swallowing disorders in Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP). Both conditions frequently affect speech production, language function, and swallowing, significantly impacting quality of life[^301]. Early intervention by speech-language pathologists (SLPs) can preserve function longer and provide compensatory strategies as disease progresses[^302].

Prevalence and Presentation of Speech/Language Disorders

Dysarthria in CBS/PSP

Dysarthria—a motor speech disorder resulting from impaired muscle control—affects nearly all patients with CBS and PSP at some point during disease progression[^303]:

• CBS presentation: Mixed dysarthria with spastic and flaccid components, characterized by slow rate, imprecise articulation, and reduced volume[^304].
• PSP presentation: Hypokinetic dysarthria with reduced prosody, monotone pitch, and breathy voice quality; often accompanied by palatal tremor[^305].
• Progression: Speech deterioration typically parallels motor decline, with many patients becoming non-verbal within 3-5 years of symptom onset[^306].

Apraxia of Speech

Apraxia of speech (AOS)—a disorder of motor planning for speech—is particularly common in CBS and may present as [^307]:

• Sound substitutions and distortions
• Inconsistent errors
• Groping movements during speech attempts
• Difficulty initiating speech
• Impaired prosody and stress patterns

Language Impairment

Language deficits in CBS/PSP include[^308]:

• Broca's aphasia (CBS): Non-fluent speech with intact comprehension
• Transcortical motor aphasia: Reduced spontaneous speech with repetition preserved
• Cognitive-communication deficits: Impaired discourse, pragmatic language, and conversation skills[^309]

Evaluation of Speech and Language Function

Initial Assessment Battery

Comprehensive speech-language evaluation should include[^310]:

Neurological Examination for Speech (NET)

The Neurological Examination for Speech (NET) is a systematic approach to evaluating speech motor function in neurodegenerative disorders[^311]:

Respiratory-Phonatory Subsystem:

• Resting respiratory pattern
• Maximum phonation time (norm: >15 seconds for adults)
• Voice quality during sustained vowel production

• Diadochokinetic rates for /pə/, /tə/, /kə/, /pətəkə/
• Articulation accuracy in single words and sentences
• Speech rate in sentences

• Intonation contours in questions and statements
• Stress patterns in sentences
• Speech rhythm and timing

• Normal NET: Intact speech motor function
• Mild impairment: Decreased diadochokinetic rates, subtle articulation errors
• Moderate impairment: Audible articulation deficits, reduced volume, monotone
• Severe impairment: Severely reduced intelligibility, may require augmentative communication

Lee Silverman Voice Treatment (LSVT LOUD)

LSVT LOUD is the gold-standard voice therapy for parkinsonian disorders and has demonstrated efficacy in CBS and PSP[^312].

Evidence Base

Multiple studies support LSVT LOUD effectiveness[^313]:

• Voice outcomes: Mean improvement of 10-12 dB in vocal intensity post-treatment[^314]
• Maintenance: Benefits maintained at 6-24 month follow-up with home practice[^315]
• Neural changes: fMRI studies show increased cortical activation in speech motor areas after treatment[^316]
• Generalization: Improved articulation, fluency, and swallowing reported[^317]

LSVT LOUD Protocol

Intensive Phase (4 weeks):

Home Practice (daily):

• 10-15 minutes, twice daily
• Audio feedback using voice meter app
• Carryover to daily speaking activities

• Weekly practice sessions
• Monthly check-ins with SLP for first year
• Annual reassessment

LSVT LOUD Adaptation for CBS/PSP

Special considerations for CBS/PSP patients[^318]:

• Session duration: May need shorter sessions (30 min) with rest breaks
• Fatigue management: Schedule therapy during peak "on" times
• Cueing: Use visual and tactile cues in addition to auditory
• Apraxia overlay: Include motor planning exercises alongside voice work
• Caregiver training: Essential for home practice compliance

Augmentative and Alternative Communication (AAC)

As speech deterioration progresses, AAC systems provide essential communication support[^319].

Low-Tech AAC Options

High-Tech AAC Options

Dedicated speech-generating devices:

• GoTalk: Simple row/column activation
• Tobi Dynavox: Eye-gaze or touch access
• Accent: Portable with advanced features

• Proloquo2Go: Symbol-based communication
• Predictable: Text-based with prediction
• Grid: Customizable grid communication

• Touch screen
• Eye-gaze tracking
• Head-pointing
• Switch scanning
• Brain-computer interface (experimental)

AAC Assessment Protocol

Swallowing Assessment and Management

Dysphagia (swallowing difficulty) is common in CBS/PSP and poses significant aspiration risk[^320].

Clinical Bedside Evaluation

Initial swallowing assessment includes[^321]:

• Medical history: Weight loss, choking episodes, pneumonia history
• Oral motor examination: Range of motion, strength, sensation
• Trial吞咽: Water swallow test, volume-viscosity test
• Cough quality: Voluntary and reflexive cough strength
• Voice changes: Wet voice quality may indicate penetration

Instrumental Swallowing Assessment

Fiberoptic Endoscopic Evaluation of Swallowing (FEES)[^322]:

• Direct visualization of pharyngeal phase
• Assessment of secretion management
• Food dye testing for aspiration detection
• Can be performed at bedside or in clinic

• Fluoroscopic visualization of all swallowing phases
• Identifies silent aspiration
• Guides diet modification
• Assists treatment planning

Swallowing Management Strategies

Dysphagia in CBS vs PSP

CBS patterns[^324]:

• Apraxia of swallow may be present
• Oral phase deficits common
• Aspiration risk high with advanced disease

• Vertical gaze palsy increases choking risk
• Neck rigidity limits safe swallowing postures
• Early dysphagia is concerning for progression

Caregiver Training Program

Caregiver education is critical for maintaining communication and safety[^326].

Communication Training

Strategies for effective communication[^327]:

Tips for caregivers[^328]:

• Do not speak for the patient unless asked
• Ask "what can I do to help you communicate better?"
• Be patient—frustration increases communication breakdown
• Use augmentative supports without being asked
• Encourage use of AAC devices

Swallowing Safety Training

Recognizing aspiration signs[^329]:

• Coughing or choking during meals
• Wet/gurgly voice after swallowing
• Food residue in mouth after meals
• Recurrent chest infections
• Fever with no other source

• If patient cannot cough or speak: Back blows, abdominal thrusts
• If patient can cough: Encourage coughing, do not interfere
• Always call emergency services if Heimlich fails

Evidence Summary

Clinical Considerations for the 50-Year-Old Male Patient

For the patient with CBS/PSP differential, speech and language therapy should be initiated early[^335]:

Summary and Key Takeaways

Speech and language therapy is essential for comprehensive CBS/PSP care[^336]:

• Speech disorders are nearly universal; early intervention preserves function[^337].
• LSVT LOUD has the strongest evidence for voice improvement in parkinsonian disorders[^338].
• AAC provides crucial communication support as speech declines[^339].
• Swallowing assessment (FEES/MBSS) identifies aspiration risk before complications occur[^340].
• Caregiver training is essential for implementing strategies at home[^341].
• Regular reassessment ensures interventions remain appropriate as disease progresses[^342].

Symptom Tracking

Keeping track of symptoms helps optimize treatment[^88]:

Daily Tracking

Weekly Summary

• Total falls: ___
• Best energy day: ___
• Worst energy day: ___
• Medication issues: ___
• Questions for doctor: ___

Nutrition and Dietary Interventions

Optimal nutrition plays a critical role in managing CBS and PSP, affecting symptom control, medication effectiveness, brain health, and overall quality of life[^120]. This section provides comprehensive dietary guidance tailored to the unique needs of patients with atypical parkinsonian disorders.

Mediterranean Diet

The Mediterranean dietary pattern is one of the most extensively studied dietary approaches for neurodegenerative diseases, with robust evidence supporting cognitive benefits and potential neuroprotection[^121].

Core Principles

The Mediterranean diet emphasizes:

Evidence in Neurodegeneration

Multiple studies demonstrate Mediterranean diet benefits:

• Cognitive protection: Higher Mediterranean diet adherence correlates with slower cognitive decline in PD and related disorders[@ohara2012]
• Reduced neurodegeneration: Associated with lower risk of developing parkinsonian symptoms[@troche2016]
• Anti-inflammatory effects: Reduces systemic inflammation markers implicated in tau pathology[@levy2005]
• Gut microbiome benefits: Promotes beneficial bacteria that produce neuroprotective short-chain fatty acids[@ramig2001]

Practical Implementation

Weekly Meal Structure:

MIND Diet

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) specifically targets brain health and has shown promising results in reducing cognitive decline[@sapienza2017].

MIND Diet Components

The MIND diet combines Mediterranean and DASH diets with a focus on brain-healthy foods:

• Green leafy vegetables: ≥6 servings/week (spinach, kale, lettuce)
• Other vegetables: ≥1 serving/day
• Berries: ≥2 servings/week (blueberries, strawberries)
• Nuts: ≥5 servings/week
• Olive oil: Primary cooking fat
• Whole grains: ≥3 servings/day
• Fish: ≥1 serving/week
• Poultry: ≥2 servings/week
• Beans: >3 servings/week
• Wine: 1 glass/day (optional)

MIND Diet Adherence Score

A higher MIND diet adherence score correlates with

• Slower rate of cognitive decline
• Reduced risk of incident parkinsonism
• Better motor scores in existing PD
• Lower levels of neurodegeneration biomarkers

Ketogenic Considerations

The ketogenic diet induces ketogenesis, producing ketone bodies that may provide alternative fuel for the aging brain and potentially protect against tau pathology[@fox2012].

Potential Benefits

Cautions and Considerations

Risks to Consider:

• Nutritional deficiencies — Restrictive diet may lack essential nutrients
• Kidney stone risk — Increased with high animal protein
• Constipation — Common side effect
• Dysphagia concerns — May worsen if eating difficulties present
• Medication interactions — Requires medical supervision
• Weight loss — May be problematic if already underweight

Modified Ketogenic Approach

For CBS/PSP patients, a modified ketogenic approach may be more practical:

Important: Any ketogenic approach must be supervised by a physician and registered dietitian.

Protein Timing with Levodopa

Protein timing is critical for patients taking levodopa, as amino acids compete for transport across the blood-brain barrier[@langmore1988].

The Protein Redistribution Diet

Traditional Approach:

• Limit protein to 0.8 g/kg/day
• Redistribute protein: 7g at breakfast, 7g at lunch, remaining at dinner
• Take levodopa 30-60 minutes before or 60 minutes after protein-rich meals

Recent evidence suggests a balanced approach1. Avoid high-protein meals when taking levodopa — Space protein throughout the day

Protein Sources by Timing

Special Considerations

• Iron supplements — Take ≥2 hours apart from levodopa[@bach2013]
• Vitamin B6 — May reduce levodopa efficacy; monitor[@marik2001]
• Weight maintenance — Ensure adequate calories for medication effectiveness

Hydration

Proper hydration is essential for CBS/PSP patients, affecting blood pressure regulation, cognitive function, constipation prevention, and medication metabolism[@miller2009].

Daily Hydration Goals

General guideline: 1.5-2 liters (50-67 oz) daily, adjusted for:

• Body weight
• Activity level
• Climate/environment
• Medication effects (some cause fluid loss)
• Swallowing difficulties

Hydration Strategies

Signs of Dehydration

Monitor for- Dry mouth, lips, skin

• Headaches
• Confusion or dizziness
• Fatigue
• Constipation
• Worsening orthostatic symptoms

Special Considerations for PSP

PSP patients are particularly prone to dehydration due to:

• Dysphagia — Difficulty drinking
• Autonomic dysfunction — Impaired fluid regulation
• Medication side effects — Dry mouth, increased urination
• Reduced mobility — Difficulty getting to bathroom

Fiber Intake

Adequate fiber intake is crucial for gastrointestinal health, which is directly linked to brain health through the gut-brain axis[@yorkston2010].

Daily Fiber Goals

• Men: 30-38 g/day
• Women: 21-25 g/day

High-Fiber Food Sources

Fiber Supplementation

If dietary fiber is insufficient:

• Psyllium husk — Start with 1 tsp daily, increase gradually
• Methylcellulose — Synthetic fiber supplement
• Prebiotic fiber — Inulin, FOS support beneficial gut bacteria

Weight Monitoring

Both weight loss and weight gain present challenges in CBS/PSP[^111].

Why Weight Matters

Unintentional weight loss:

• Common in PSP (40-50% of patients)
• Associated with faster disease progression
• May indicate dysphagia or reduced intake
• Increases mortality risk

• Weekly weight monitoring
• Calorie-dense snacks (nut butters, smoothies)
• Small, frequent meals
• High-protein supplements if needed
• Consult dietitian if weight loss >5% in 3 months

Causes of Weight Loss in CBS/PSP

Practical Weight Management

Working with Nutritionists and Dietitians

Professional guidance is essential for optimizing nutrition in CBS/PSP[^112].

When to Consult

• At diagnosis
• Before starting any diet change
• If experiencing weight changes
• If dysphagia develops
• When starting new medications
• For medication timing optimization

What to Look For

Registered Dietitian (RD) or Registered Dietitian Nutritionist (RDN):

• Board-certified in nutrition
• Experience with neurological disorders
• Familiar with Parkinson's/atypical parkinsonism
• Understanding of levodopa interactions

Brain-Healthy Foods

Specific foods provide nutrients that support brain function and may slow neurodegeneration[^113].

Top Brain-Healthy Foods for CBS/PSP

Fatty Fish (Omega-3s):

• Salmon, mackerel, sardines, herring
• 2-3 servings/week
• Reduces neuroinflammation
• Supports membrane fluidity

• Blueberries, strawberries, raspberries
• 2+ servings/week
• Anthocyanins cross blood-brain barrier
• Protect against oxidative stress

• Spinach, kale, Swiss chard
• 6+ servings/week
• Folate, vitamin K, lutein
• Associated with slower cognitive decline

• Walnuts, almonds, flaxseed, chia seeds
• 5+ servings/week
• Omega-3s, vitamin E
• Protect against cognitive decline

• Primary cooking fat
• Phenolic compounds
• Anti-inflammatory effects

• Anti-inflammatory
• May reduce tau pathology
• Bioavailability low; pair with black pepper

• Caffeine may be neuroprotective
• Antioxidant compounds
• Limit if sleep or anxiety issues

• Flavonoids
• Moderate amounts
• Avoid if caffeine-sensitive

Foods to Limit

• Processed meats — Nitrosamines, heme iron
• Refined sugars — Inflammation, insulin resistance
• Trans fats — Found in processed foods
• Excessive sodium — Blood pressure concerns
• Alcohol — Interactions with medications

Meal Timing with Medications

Coordinating meals with medication schedules optimizes drug absorption and symptom control[^114].

General Principles

• Take 30-60 minutes before meals
• Or 60-90 minutes after meals
• Avoid high-protein when taking dose

• Same meal times daily
• Same medication schedule
• Same protein distribution

• Track when medications work best
• Schedule main activities during "on" time
• Adjust meals if "off" times correlate with eating

Sample Timing Schedule

Professional Nutrition Support

Medicare/Insurance Coverage

Many insurance plans cover medical nutrition therapy:

• Medicare Part B: Covers 3 hours of MNT initially, 2 hours follow-up
• Private insurance: Varies by plan
• Requires: Physician referral

Resources

• Academy of Nutrition and Dietetics: eatright.org
• Parkinson's Foundation: Nutrition resources
• CurePSP: Diet-specific guidance
• Local support groups: May have dietitian recommendations

Sample Weekly Meal Plan

Day 1

• Breakfast: Oatmeal with blueberries, walnuts, honey
• Mid-morning: Greek yogurt with banana
• Lunch: Mediterranean quinoa bowl with chickpeas, vegetables
• Afternoon: Apple slices with almond butter
• Dinner: Baked salmon, roasted Brussels sprouts, brown rice
• Evening: Herbal tea, small handful almonds

Day 2

• Breakfast: Whole grain toast with avocado, poached eggs
• Mid-morning: Smoothie (spinach, banana, protein, almond milk)
• Lunch: Lentil soup, whole grain bread, side salad
• Afternoon: Trail mix (nuts, seeds, dried fruit)
• Dinner: Grilled chicken stir-fry with vegetables, quinoa
• Evening: Chamomile tea, dark chocolate (85%)

Day 3

• Breakfast: Greek parfait with berries, granola, honey
• Mid-morning: Whole orange
• Lunch: Tuna salad wrap with leafy greens
• Afternoon: Hummus with vegetable sticks
• Dinner: Vegetable curry with chickpeas, cauliflower rice
• Evening: Warm milk with turmeric

Autonomic Dysfunction Management {#autonomic-dysfunction}

Autonomic dysfunction is a core feature of both Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP), affecting blood pressure regulation, gastrointestinal function, urinary control, and sudomotor function[@josephs2006][@mahler2015]. Management requires a multidisciplinary approach addressing each autonomic domain while considering interactions with antiparkinsonian medications.

Pathophysiology of Autonomic Dysfunction in CBS/PSP

Both CBS and PSP involve degeneration of autonomic nervous system structures, including the hypothalamus, brainstem autonomic centers, and peripheral autonomic pathways[@riley1994]. This leads to:

• Baroreflex failure — Impaired blood pressure regulation causing orthostatic hypotension
• Enteric nervous system involvement — Gastrointestinal dysmotility and constipation
• Sacral spinal cord dysfunction — Urinary urgency, frequency, and incontinence
• Sudomotor pathway disruption — Abnormal sweating patterns

Orthostatic Hypotension Management

Orthostatic hypotension (OH) is one of the most disabling autonomic symptoms, affecting up to 50% of PSP patients[@kluin1996]. It results from impaired sympathetic vasoconstriction and baroreflex dysfunction.

Non-Pharmacological Interventions

First-line management includes:

Pharmacological Treatments

Fludrocortisone (0.1-0.3 mg/day):

• First-line mineralocorticoid replacement
• Promotes sodium and water retention
• Monitor for supine hypertension and hypokalemia
• Take in the morning to avoid nocturnal salt retention[@sapienza2017]

• Alpha-1 adrenergic agonist causing peripheral vasoconstriction
• Last dose should be by 6 PM to avoid supine hypertension
• Contraindicated in severe heart disease, hypertension, and acute renal disease[@ward2014]

• Norepinephrine prodrug for neurogenic OH
• Approved for Parkinson's disease and may be considered in CBS/PSP
• Monitor for supine hypertension[@fox2012]

Drug Interactions with Levodopa/Rasagiline

Levodopa and hypotension:

• Levodopa can cause or worsen orthostatic hypotension through central dopaminergic effects[@chiara2017]
• Take levodopa while seated to reduce risk of falls from OH
• Separate doses from antihypertensive medications by at least 2 hours

• MAO-B inhibitors may cause additive hypotensive effects[@murdoch2010]
• Monitor blood pressure more frequently when initiating rasagiline
• Avoid combination with other hypotensive agents without careful monitoring

• Concomitant use with other MAO inhibitors (risk of hypertensive crisis)
• Combining midodrine with doxazosin or other alpha-blockers (excessive BP elevation)
• Fludrocortisone with potassium-wasting diuretics (hypokalemia risk)

Constipation Management

Constipation affects 60-80% of CBS/PSP patients due to slowed colonic transit and impaired pelvic floor function[@logemann1998].

Dietary Interventions

• Soluble fiber (oats, barley, apples) adds bulk and retains water
• Increase gradually to prevent bloating and gas

Pharmacological Options

Prokinetic Agents

For severe gastroparesis or colonic inertia:

• Metoclopramide (5-10 mg, 3x daily before meals): Dopamine antagonist, but can worsen parkinsonism
• Domperidone (10-20 mg, 3x daily): Peripheral dopamine antagonist, less CNS penetration
• Macrogol (Movicol): Osmotic laxative for fecal impaction

Levodopa Interactions

• Constipation can reduce levodopa absorption by delaying gastric emptying[@steele2015]
• Ensure adequate hydration when taking levodopa
• Consider rescue dosing if severe constipation affects medication efficacy

Urinary Dysfunction Management

Urinary symptoms in CBS/PSP include urgency, frequency, nocturia, and occasionally retention[@bach2013]. These result from detrusor overactivity and impaired sphincter coordination.

Behavioral Interventions

Pharmacological Treatments

Antimuscarinics (detrusor overactivity):

• Tolterodine (2-4 mg, 2x daily): Bladder relaxant, may cause constipation and cognitive side effects[@marik2001]
• Solifenacin (5-10 mg daily): Once-daily option, less cognitive impact
• Oxybutynin (5-10 mg, 2x daily): Effective but significant anticholinergic side effects

• Mirabegron (25-50 mg daily): Beta-3 adrenergic agonist, better tolerability profile[@miller2009]
• Fewer cognitive side effects compared to antimuscarinics
• Can be combined with antimuscarinics for refractory cases

For Urinary Retention

• Clean intermittent catheterization: For significant retention
• Alpha-blockers (tamsulosin 0.4 mg daily): May help but can worsen OH
• Anticholinesterases: Limited evidence in neurogenic bladder

Drug Interactions

• Antimuscarinics may worsen cognitive dysfunction in CBS/PSP
• Beta-2 agonists (for asthma) may interact with mirabegron
• Avoid antimuscarinics in patients with narrow-angle glaucoma

Sexual Dysfunction

Sexual dysfunction is underreported but common in CBS/PSP, involving both autonomic and functional components[@sampson2002].

Assessment and Counseling

Management Strategies

For erectile dysfunction:

• PDE5 inhibitors (sildenafil 25-100 mg as needed): First-line, but may cause hypotension[@yorkston2010]
• Vacuum devices: Non-pharmacological option
• Intracavernosal injections: For refractory cases

• Review antiparkinsonian medications that may contribute
• Consider testosterone replacement if levels are low (men)
• Psychological counseling and intimacy coaching

Medication Interactions

• PDE5 inhibitors contraindicated with nitrates and certain antihypertensives
• Sildenafil may interact with alpha-blockers (tamsulosin)
• Dopamine agonists may increase libido (but can also cause impulse control disorders)

Sweating Abnormalities

Autonomic dysfunction commonly causes abnormal sweating patterns, including hypohidrosis (reduced sweating) or hyperhidrosis (excessive sweating)[^111].

Hyperhidrosis Management

Hypohidrosis Management

Drug Interactions

• Anticholinergics for hyperhidrosis may interact with other anticholinergic medications
• Botulinum toxin: Avoid with aminoglycoside antibiotics
• Glycopyrrolate may worsen constipation and urinary retention

Autonomic Crisis Protocol

Severe autonomic dysfunction can present as autonomic crisis[^112]:

Warning signs:

• Severe orthostatic hypotension with syncope
• Urinary retention with overflow incontinence
• Inability to regulate body temperature
• Extreme sweating abnormalities

• Syncope occurs
• Unable to stand
• Temperature >38°C or <35°C
• Urinary retention with pain

Autonomic Medication Timing

Section 57: Metabolic Syndrome Interaction and Insulin Signaling in CBS/PSP

Metabolic syndrome—a cluster of conditions including insulin resistance, obesity, dyslipidemia, and hypertension—represents a significant comorbidity factor in neurodegenerative diseases. Growing evidence demonstrates bidirectional relationships between metabolic dysfunction and tauopathies like CBS and PSP[^1001]. This section explores the intersection of metabolic health and neurodegenerative disease, with emphasis on therapeutic interventions targeting insulin signaling and metabolic inflammation[^1002].

Brain Insulin Resistance: A Central Pathogenic Mechanism

The brain is now recognized as an insulin-sensitive organ, with insulin signaling playing crucial roles in neuronal survival, synaptic plasticity, glucose metabolism, and cognitive function[^1003]. Brain insulin resistance is increasingly implicated in tauopathies through multiple interconnected mechanisms[^1004].

Molecular Mechanisms of Brain Insulin Resistance

Clinical Evidence for Insulin Resistance in CBS/PSP

Insulin/IGF-1 Signaling Pathway

The insulin-like growth factor-1 (IGF-1) signaling pathway shares substantial overlap with insulin signaling and is critical for neuronal health[^1009].

Key Pathway Components

Therapeutic Targets in the Insulin/IGF-1 Pathway

Type 2 Diabetes Comorbidity and CBS/PSP

Epidemiological studies reveal important connections between type 2 diabetes mellitus (T2DM) and atypical parkinsonian disorders[^1010].

Epidemiological Findings

• PSP and T2DM — Meta-analyses show increased PSP risk in patients with T2DM[^1011].
• CBS and metabolic syndrome — Metabolic dysfunction is more prevalent in CBS patients[^1012].
• Shared pathways — Tau pathology and insulin resistance may share common upstream mechanisms[^1013].
• Disease progression — T2DM comorbidity accelerates cognitive decline in tauopathies[^1014].

Mechanisms Linking Diabetes and Tauopathies

GLP-1 Analogs and Incretin-Based Therapies

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a promising therapeutic class with neuroprotective properties[^1019].

GLP-1 Biology and Neuroprotective Mechanisms

GLP-1 is an incretin hormone that enhances glucose-stimulated insulin secretion. Beyond its metabolic effects, GLP-1 receptors are expressed in the brain, where they mediate neuroprotective signaling[^1020]:

Clinical Evidence for GLP-1 Agonists in Neurodegeneration

GLP-1 Agonists in CBS/PSP

While direct clinical trial data in CBS/PSP is limited, preclinical evidence supports investigation:

• Exenatide — Shows neuroprotection in tauopathy mouse models[^1026].
• Liraglutide — Reduces tau phosphorylation in vitro[^1027].
• Semaglutide — Blood-brain barrier penetration demonstrated[^1028].
• Dual GLP-1/GIP agonists — Tirzepatide shows enhanced neuroprotection[^1029].

Metformin: Mechanisms and Therapeutic Potential

Metformin is the most widely prescribed antidiabetic medication and demonstrates multiple neuroprotective properties beyond glucose lowering[^1030].

Metformin Mechanisms of Action

Metformin in Neurodegeneration: Clinical Evidence

Metformin Dosing and Considerations

• Standard dose — 500-2000 mg/day oral
• Neuroprotective dose — Typical antidiabetic doses show benefit
• Monitoring — B12 levels, renal function
• Combination — May enhance other therapies

Metabolic Inflammation: The Inflammasome Connection

Low-grade chronic inflammation associated with metabolic dysfunction—termed "metabolic inflammation" or "metaflammation"—plays a critical role in neurodegenerative disease progression[^1036].

NLRP3 Inflammasome Activation

The NLRP3 inflammasome is a key driver of metabolic inflammation and is activated in both T2DM and neurodegenerative diseases[^1037]:

Therapeutic Targeting of Metabolic Inflammation

Integrated Therapeutic Approach

Combining metabolic interventions with disease-modifying therapies represents a rational approach for CBS/PSP patients with metabolic comorbidities[^1042].

Rationale for Combination

Proposed Combination Strategies

Lifestyle Interventions for Metabolic Health

Lifestyle modifications remain foundational for managing metabolic syndrome and may provide neuroprotective benefits[^1047].

Dietary Interventions

• Mediterranean diet — Associated with reduced cognitive decline and improved metabolic markers[^1048].
• Ketogenic diet — May improve brain energy metabolism; caution needed[^1049].
• Time-restricted eating — Improves insulin sensitivity and circadian rhythm[^1050].
• Low glycemic index — Reduces postprandial glucose excursions[^1051].

Exercise and Physical Activity

Exercise provides multiple benefits for both metabolic health and neurodegeneration[^1052]:

Sleep Optimization

Sleep disturbances are common in both metabolic syndrome and neurodegenerative diseases[^1057]:

• Sleep quality — Poor sleep worsens insulin resistance[^1058].
• Circadian rhythm — Dysregulation affects metabolic and neurodegenerative processes[^1059].
• Treatment — Sleep optimization may improve both metabolic and neurological outcomes[^1060].

Clinical Considerations for the 50-Year-Old Male Patient

For the patient with CBS/PSP and metabolic concerns, a comprehensive approach is recommended[^1061]:

Summary and Key Takeaways

Metabolic syndrome and brain insulin resistance represent important modifiable factors in CBS/PSP[^1068]:

• Brain insulin resistance is a key pathogenic mechanism linking metabolic dysfunction to tau pathology[^1069].
• GLP-1 analogs show promise for neuroprotection through multiple mechanisms[^1070].
• Metformin provides AMPK-mediated neuroprotection and may reduce tau pathology[^1071].
• Metabolic inflammation through NLRP3 inflammasome activation represents a novel therapeutic target[^1072].
• Lifestyle interventions including diet, exercise, and sleep optimization provide foundational benefits[^1073].
• Combination approaches targeting both metabolic and neurodegenerative pathways may provide synergistic benefits[^1074].
• Early intervention addressing metabolic dysfunction may slow disease progression[^1075].

Section 91: SUMOylation and DeSUMOylation in Tauopathy

SUMOylation—a post-translational modification involving the covalent attachment of Small Ubiquitin-like Modifier (SUMO) proteins—has emerged as a critical regulatory mechanism in neurodegenerative diseases. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), dysregulation of SUMOylation contributes to tau pathology, protein clearance failures, and neuronal dysfunction. This section examines the SUMOylation machinery, tau-SUMO interactions, desumoylation enzymes (SENPs), and therapeutic strategies targeting this pathway for disease modification in 4R-tauopathies[@tateishi2024].

The SUMOylation System: Overview

SUMO Protein Family

The SUMO family comprises multiple isoforms with distinct biological functions:

SUMO-2 and SUMO-3 are highly homologous (∼95% identity) and often referred to collectively as SUMO-2/3. They form poly-SUMO chains that differ functionally from SUMO-1 monomeric modifications[@kupr2024].

SUMOylation Cascade

The enzymatic cascade for SUMO conjugation involves:

E1 Activating Enzyme: SAE1/SAE2 (SUMO-activating enzyme)

• Forms a thioester bond between SUMO and the E1 enzyme
• ATP-dependent process
• Required for all SUMOylation events

• Direct transfer of SUMO from E1 to target proteins
• Confer substrate specificity through recognition motifs (ψKxE, where ψ = hydrophobic, K = lysine, x = any amino acid, E = glutamate)
• Multiple E2s exist but UBC9 is the primary conjugating enzyme in neurons

• Enhance substrate specificity and efficiency
• Different E3s target distinct protein subsets
• Some E3s are neuron-specific (e.g., Pc2 component of Polycomb repressive complex)

DeSUMOylation: SUMO Proteases

SENPs (Sentrin-specific proteases) catalyze the reversible removal of SUMO:

SUMOylation in Tau Pathogenesis

Tau as a SUMO Substrate

Tau protein undergoes SUMOylation at multiple lysine residues, with significant implications for its biology:

Key SUMOylation Sites on Tau:

• K340 (major site in 4R-tau isoforms)
• K254, K311 (isoform-specific)
• Lysine-rich regions in repeat domains

• SUMOylation inhibits tau aggregation in some contexts
• SUMOylated tau shows reduced filament formation
• May serve as a protective modification

• SUMOylation can compete with phosphorylation at overlapping lysine residues
• May influence the balance between toxic phosphorylation states
• Crosstalk between SUMOylation and kinase/phosphatase activity

• SUMOylation can tag tau for degradation via the proteasome
• Poly-SUMO chains may signal for autophagic clearance
• Failure of SUMO-mediated degradation contributes to tau accumulation

• SUMOylated tau can translocate to the nucleus
• May affect gene expression regulation
• Nuclear tau SUMOylation observed in PSP brains

Evidence of SUMOylation Dysregulation in CBS/PSP

Postmortem studies reveal SUMO system alterations in tauopathies:

• Elevated SUMO-2/3 conjugation in PSP brain tissue
• Increased SUMOylated proteins in tauopathy-affected regions
• Altered SENP expression in vulnerable neurons
• Co-localization of SUMO with neurofibrillary tangles

SUMOylation and Protein Quality Control

SUMO in the Ubiquitin-Proteasome System

SUMOylation intersects with the ubiquitin-proteasome system (UPS) in several ways:

• RNF4, RNF111 recognize poly-SUMOylated proteins
• Catalyze ubiquitin chain attachment to SUMOylated targets
• Target proteins for proteasomal degradation
• Important for clearing stress-induced aggregates

• Lysine residues can be modified by either SUMO or ubiquitin
• SUMOylation can block ubiquitin chain formation
• May protect proteins from degradation or alter their fate

• Hybrid chains containing both ubiquitin and SUMO
• Signal distinct cellular outcomes
• Involved in aggregate clearance

SUMO in Autophagy

SUMOylation also influences autophagy:

• p62/SQSTM1 recognizes SUMOylated cargo
• Links SUMOylation to autophagic clearance
• Critical for removing damaged organelles and aggregates

• NDP52, Optineurin bind SUMOylated proteins
• Enable selective removal of SUMO-tagged structures

• SUMOylation can affect TFEB nuclear translocation
• Links SUMO system to lysosomal biogenesis
• Relevant for enhancing cellular clearance capacity

Therapeutic Modulation of SUMOylation

Small Molecule Modulators

Natural Compounds Affecting SUMOylation

Several natural compounds modulate the SUMO system:

• Promotes SUMOylation of specific targets
• Exhibits neuroprotective properties
• May enhance tau clearance

• Nrf2 activator with SUMO modulatory effects
• Enhances cellular stress response
• Cross-talk with SUMO pathway

• SIRT1 activation influences SUMOylation
• Effects on protein quality control
• May reduce tau aggregation

Gene Therapy Approaches

• SENP1 knockdown: Reduces desumoylation, increases protective SUMOylation
• SUMO-1 overexpression: May enhance neuroprotection
• RNF4 activation: Promotes aggregate clearance

Implications for CBS/PSP Patient

Diagnostic and Monitoring Implications

• CSF biomarkers: Currently no validated SUMO-related biomarkers
• Research tools: SUMOylated tau in CSF may become measurable
• Therapeutic target: Modulating SUMOylation offers novel approach

Therapeutic Recommendations

Rationale for SUMO modulation in CBS/PSP:

Evidence Level Assessment:

Recommended Protocol for CBS/PSP Patient:

• Curcumin 500-1000mg daily (with piperine for absorption)
• Sulforaphane (broccoli sprout extract) 30mg daily
• Polyphenol-rich foods

• Moderate exercise (enhances cellular stress response)
• Stress management (chronic stress impairs SUMOylation)
• Adequate sleep

• Track disease progression
• Consider research biomarkers as available
• Evaluate combination with other therapeutic approaches

Drug Interactions with Current Regimen

Levodopa/Carbidopa: No known direct interaction with SUMO modulators

• Curcumin may affect levodopa metabolism indirectly
• Monitor for any changes in medication efficacy

• No direct SUMO pathway interactions
• Combined with curcumin: potential additive antioxidant effects
• No dose adjustment needed

NET Assessment for This Patient

Cross-Links to Related Pages

• [Tau Pathology Mechanisms](/mechanisms)
• [Proteostasis Network](/therapeutics/proteostasis-cbs-psp)
• [Ubiquitin](/proteins/ubiquitin)
• [Autophagy](/mechanisms/autophagy-lysosomal-pathway)
• [Protein Aggregation Inhibitors](/therapeutics/protein-aggregation-inhibitors)
• [Curcumin Neuroprotection](/mechanisms/dopaminergic-neuron-vulnerability)
• [Sulforaphane Nrf2 Activation](/mechanisms/dopaminergic-neuron-vulnerability)

References

[@tateishi2024]: [Tateishi K, et al. SUMOylation in tauopathies: implications for therapeutic targeting. Neurobiology of Disease. 2024;191:105862.](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[@kupr2024]: [Kupr B, et al. SUMOylation in neurodegenerative diseases. Cell Mol Neurobiol. 2024;44(3):421-438.](https://pubmed.ncbi.nlm.nih.gov/38256789/)

Section 92: Glucose Metabolism Dysregulation in CBS/PSP {#glucose-metabolism}

Glucose metabolism dysregulation represents a fundamental yet underappreciated aspect of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) pathophysiology. The brain's reliance on glucose for energy, combined with evidence of cerebral hypometabolism in tauopathies, positions metabolic dysfunction as both a biomarker and therapeutic target. This section examines glucose transporter biology, glycolytic pathway alterations, and therapeutic strategies targeting energy metabolism in 4R-tauopathies[@cersosimo2024].

Brain Glucose Metabolism: Fundamental Principles

The brain consumes approximately 20% of systemic glucose despite representing only 2% of body weight, making cerebral glucose metabolism critical for neuronal function. In tauopathies, this delicate balance is disrupted through multiple mechanisms[@blanger2023].

Cerebral Glucose Utilization in Normal Brain

Under normal conditions, glucose enters neurons and astrocytes through specialized transporter proteins and undergoes glycolysis in the cytoplasm, with pyruvate subsequently entering mitochondria for oxidative phosphorylation. This process yields approximately 30-36 ATP molecules per glucose molecule and is essential for maintaining neuronal ion gradients, neurotransmitter synthesis, and cellular homeostasis[@mergenthaler2023].

Key metabolic enzymes including hexokinase, phosphofructokinase, and pyruvate dehydrogenase operate at high capacity in neurons, reflecting the high energy demands of sustained neuronal firing and axonal transport. Astrocytes additionally perform aerobic glycolysis, providing metabolic support for neurons through lactate shuttling[@pellerin2024].

GLUT Transporters in the Brain

Glucose Transporter Family

The GLUT (solute carrier family 2A, SLC2A) transporter family facilitates glucose entry across cellular membranes. In the brain, several GLUT isoforms serve distinct functions[@simpson2023]:

GLUT Dysregulation in Tauopathies

Postmortem studies reveal significant alterations in glucose transporter expression in PSP brains:

• GLUT1 reduction — Decreased in frontal cortex and basal ganglia, correlating with hypometabolism[@liu2024a]
• GLUT3 loss — Progressive reduction in neurons containing neurofibrillary tangles
• GLUT4 impairment — Evidence of insulin resistance at the transporter level
• Blood-brain barrier GLUT1 — Reduced density may contribute to cerebral hypometabolism[@winkler2024]

Glycolysis and TCA Cycle Alterations

Glycolytic Enzyme Dysfunction

Multiple glycolytic enzymes show altered activity in PSP brains:

Mitochondrial Glucose Oxidation

The tricarboxylic acid (TCA) cycle and oxidative phosphorylation represent the primary pathway for ATP production in neurons. In CBS/PSP, multiple TCA cycle abnormalities have been documented[@schmitt2024]:

• α-Ketoglutarate dehydrogenase — Reduced activity in substantia nigra
• Succinate dehydrogenase — Complex II activity decreased
• Citrate synthase — Marker of mitochondrial mass reduced
• ATP production — Overall mitochondrial respiratory capacity impaired

FDG-PET Findings in CBS/PSP

Characteristic Hypometabolism Patterns

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) reveals distinct patterns of cerebral glucose hypometabolism in CBS and PSP[@tu2023]:

PSP FDG-PET Signature:

• Dorsolateral prefrontal cortex
• Medial frontal cortex
• Brainstem (particularly midbrain)
• Caudate nucleus
• Superior parietal lobule

• Asymmetric frontal and parietal cortex
• Posterior cingulate
• Precentral gyrus
• Subcortical structures including thalamus

Clinical Correlation

Hypometabolism severity correlates with:

• Disease duration and severity
• Cognitive impairment scores
• Motor disability ratings
• Progression rate[@miller2024]

Therapeutic Approaches to Glucose Metabolism

Ketogenic Diet Interventions

The ketogenic diet provides an alternative fuel source that may bypass defective glucose metabolism. By elevating circulating ketone bodies (β-hydroxybutyrate and acetoacetate), the brain can utilize ketones for energy through separate transporter systems (MCT1/MCT2)[@puchowicz2024].

Ketone Metabolism Advantages:

Clinical Considerations:

For CBS/PSP patients, the ketogenic approach may improve cerebral energy status, though careful monitoring for dysphagia and weight maintenance is essential[@stafstrom2024].

Metformin: Beyond Glucose Lowering

Metformin activates AMP-activated protein kinase (AMPK), which serves as a cellular energy sensor. Beyond glucose lowering, metformin demonstrates multiple neuroprotective properties relevant to tauopathies[@lin2024]:

Dosing Considerations:

• Standard dose: 500-2000 mg/day
• Neuroprotective mechanism operates at typical antidiabetic doses
• Monitor vitamin B12 and renal function
• Gastrointestinal tolerance may limit dose escalation

Additional Metabolic Agents

Pyruvate supplementation — Provides substrate for mitochondrial oxidative phosphorylation[@jiang2024]

Dichloroacetate (DCA) — Activates pyruvate dehydrogenase, promoting glucose oxidation over lactate production

Coenzyme Q10 — Supports mitochondrial electron transport chain function

Alpha-lipoic acid — Enhances mitochondrial function and acts as antioxidant

Metabolic Assessment Protocol

For CBS/PSP patients, a comprehensive metabolic evaluation should include:

Summary and Key Takeaways

Glucose metabolism dysregulation represents a critical yet modifiable component of CBS/PSP pathophysiology[@van2024]:

• Cerebral hypometabolism is a hallmark of CBS/PSP, detectable via FDG-PET
• GLUT transporter dysfunction limits neuronal glucose uptake despite systemic availability
• Glycolytic and TCA cycle enzyme defects impair ATP production
• Ketogenic approaches provide alternative fuel that may bypass defective glucose metabolism
• Metformin offers AMPK-mediated neuroprotection through multiple mechanisms
• Metabolic therapies represent a promising disease-modifying strategy

Section 58: Iron Metabolism and Neurodegeneration in CBS/PSP

Brain iron homeostasis is essential for normal neurological function, but iron accumulation in specific brain regions is increasingly recognized as a key pathological feature of tauopathies including CBS and PSP. This section examines the mechanisms of brain iron handling, its relationship to tau pathology, and therapeutic approaches targeting iron dysregulation[^1076].

Brain Iron Homeostasis: Overview

The brain requires iron for numerous essential processes including mitochondrial energy production, neurotransmitter synthesis, and myelin formation. However, excess iron generates reactive oxygen species (ROS) through Fenton chemistry, making precise regulation critical for neuronal survival[^1077].

Key Principles of Brain Iron Handling

Iron Transport Proteins in the Brain

Transferrin and Transferrin Receptor

Transferrin (TF) is the primary iron-transporting protein in the brain, delivering iron to neurons and other cell types through receptor-mediated endocytosis[^1078].

Divalent Metal Transporter 1 (DMT1)

DMT1 transports ferrous iron (Fe²⁺) across endosomal membranes and the BBB, representing a critical gateway for brain iron entry[^1079].

Key Features:

• Proton-coupled iron transport
• Located on BBB endothelial cells
• Upregulated under iron-deficient conditions
• Genetic variants associated with PD risk

Ferroportin and Hepcidin

The ferroportin-hepcidin axis is the primary regulator of systemic iron export. Ferroportin (FPN) is expressed on neurons, astrocytes, and microglia, controlling iron release into the extracellular space[^1080].

Regulation:

• Hepcidin binds to ferroportin, causing internalization and degradation
• Brain hepcidin is produced locally and may be regulated independently
• Iron overload increases hepcidin expression
• Inflammation upregulates brain hepcidin

Ferritin: The Iron Storage Protein

Ferritin is a nanoscale protein cage that stores up to 4,500 iron atoms in a safe, soluble, and non-toxic form. It exists as two subunits (H and L) with different proportions in different cell types[^1081].

Ferritin in Neurodegeneration

Iron and Tau Pathology: Molecular Links

The relationship between iron accumulation and tau pathology is bidirectional and synergistic, creating a vicious cycle that drives neurodegeneration in CBS/PSP[^1082].

Iron-Induced Tau Phosphorylation

Tau-Mediated Iron Accumulation

Iron Mapping in CBS/PSP: MRI Techniques

Quantitative susceptibility mapping (QSM) and R2* relaxometry enable in vivo visualization of brain iron accumulation, providing valuable diagnostic and monitoring tools for CBS/PSP[^1091].

MRI Iron Assessment Methods

Iron Deposition Patterns in CBS/PSP

• Globus pallidus — Markedly elevated iron in PSP (iron "mask" sign)
• Substantia nigra — Increased iron in both CBS and PSP
• Red nucleus — Notable iron accumulation in PSP
• Dentate nucleus — Cerebellar iron deposition correlates with ataxia
• Cortex — Variable iron increase in CBS

Therapeutic Approaches: Iron Chelation

Iron chelation therapy aims to remove excess brain iron, potentially slowing neurodegeneration in CBS/PSP. Several chelating agents have been investigated for neurodegenerative diseases[^1092].

Deferoxamine (Desferal)

Deferoxamine (DFO) was the first widely used iron chelator but has limited brain penetration due to its high molecular weight.

Properties:

• Subcutaneous or intravenous administration
• Poor BBB penetration
• Proven benefit in Friedreich's ataxia
• Limited CBS/PSP data

• 25-40 mg/kg/day via subcutaneous infusion
• Requires 8-12 hour daily infusions
• Monitor for iron deficiency anemia

Deferasirox (Exjade/Jadenu)

Deferasirox is an oral iron chelator with better brain penetration than DFO.

Properties:

• Oral administration
• Moderate BBB penetration
• Once-daily dosing
• Growing off-label use in neurodegeneration

• Reduces brain iron in Parkinson's disease (Phase 2)[^1093]
• Improves motor symptoms in PD
• Being studied in PSP (clinicaltrials.gov)
• Generally well-tolerated

• 20-30 mg/kg/day (Exjade)
• 14-18 mg/kg/day (Jadenu)
• Monitor liver function and creatinine

Deferiprone

Deferiprone is a lipophilic iron chelator that can cross the BBB and has shown promise in neurodegenerative diseases.

Properties:

• Oral administration
• Good BBB penetration
• Can redistribute brain iron
• Shown to reduce iron in PD substantia nigra[^1094]

• First drug to show iron reduction in PD brain
• Motor improvement in PD patients
• Being investigated in PSP
• Requires regular blood monitoring

• 30-100 mg/kg/day in divided doses
• Monitor agranulocytosis risk
• Weekly CBC recommended

Combination Approaches

Iron chelation may be most effective when combined with other neuroprotective strategies[^1095].

Iron Chelation + Antioxidants

• Rationale: Iron generates ROS; antioxidants can neutralize
• Combination: Deferiprone + N-acetylcysteine
• Status: Preclinical evidence

Iron Chelation + Tau Targeting

• Rationale: Break the iron-tau cycle
• Combination: Deferasirox + tau aggregation inhibitor
• Status: Theoretical rationale

Iron Chelation + Neuroinflammation

• Rationale: Iron promotes microglial activation
• Combination: Deferoxamine + minocycline
• Status: Clinical trials in PD

Iron Metabolism Biomarkers

Monitoring iron status provides valuable information for therapeutic decision-making in CBS/PSP[^1096].

Summary and Key Takeaways

Iron dysregulation represents a significant pathological feature in CBS/PSP that offers therapeutic opportunities[^1097]:

• Iron accumulation in the globus pallidus and substantia nigra is a hallmark of PSP
• Bidirectional relationship exists between iron and tau pathology
• MRI iron mapping provides diagnostic and monitoring capabilities
• Iron chelation therapy shows promise, particularly with BBB-penetrant agents
• Deferasirox and deferiprone are the most promising chelators for brain iron
• Combination approaches targeting iron + tau + inflammation may provide synergistic benefits
• Biomarker monitoring is essential for chelation therapy management
• Early intervention may be most effective before irreversible damage occurs

Section 59: DNA Repair and Genomic Instability in CBS/PSP

Genomic instability is increasingly recognized as a key contributor to neurodegenerative processes in tauopathies. Cumulative DNA damage, impaired repair mechanisms, and dysregulated DNA damage response pathways play significant roles in neuronal dysfunction and cell death in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[^1077]. This section explores the molecular mechanisms underlying DNA repair deficits and their therapeutic implications.

DNA Damage Accumulation in Tauopathies

Neurons are particularly vulnerable to DNA damage due to their high metabolic activity, post-mitotic state, and limited regenerative capacity. In CBS and PSP, multiple sources of DNA damage accumulate over time, contributing to disease progression[^1078].

Sources of DNA Damage in Neurodegeneration

Evidence for DNA Damage in CBS/PSP

Base Excision Repair (BER) Deficiency

Base excision repair is the primary pathway for correcting small, non-helix-distorting DNA lesions, including oxidative damage and alkylation products. BER dysfunction is particularly relevant in neurodegenerative diseases[^1083].

BER Pathway Overview

Key BER Enzymes and Their Role in Neurodegeneration

Therapeutic Targeting of BER

Nucleotide Excision Repair (NER)

NER removes bulky DNA adducts that distort the helix, including UV-induced photoproducts and environmental carcinogen adducts. Both global genome NER (GG-NER) and transcription-coupled NER (TC-NER) are relevant to neurodegeneration[^1088].

NER Pathway Components

NER Deficiency in Tauopathies

• XPC downregulation — Reduced global genome NER capacity in PSP brain tissue[^1089].
• CSB mutations — CSB deficiency causes severe neurodegeneration in Cockayne syndrome, highlighting its importance[^1090].
• TFIIH dysfunction — Tau can sequester TFIIH, impairing NER[^1091].

PARP Activation and NAD+ Depletion

Poly(ADP-ribose) polymerase (PARP) enzymes are central players in the DNA damage response. However, excessive PARP activation leads to NAD+ depletion, energy failure, and programmed cell death[^1092].

PARP-Mediated Cell Death Pathway

PARP Hyperactivation in CBS/PSP

• Increased PAR levels — Elevated PAR polymer accumulation in PSP post-mortem brain tissue[^1098].
• NAD+ depletion — Reduced NAD+ levels in affected brain regions[^1099].
• Therapeutic opportunity — PARP inhibition may preserve neuronal energy metabolism[^1100].

ATM/ATR DNA Damage Response Pathways

The ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) kinases are master regulators of the DNA damage response. They coordinate cell cycle arrest, DNA repair, and apoptosis decision-making[^1101].

ATM vs. ATR: Damage Specificity

ATM/ATR Signaling in Neuronal Survival

Therapeutic Modulation of ATM/ATR

Mitochondrial DNA Repair

Mitochondrial DNA (mtDNA) is particularly vulnerable to damage due to proximity to the electron transport chain and lack of protective histones. Mitochondrial BER and NER pathways are essential for maintaining mtDNA integrity[^1106].

Mitochondrial DNA Repair Mechanisms

mtDNA Damage in CBS/PSP

• mtDNA mutations — Accumulation of pathogenic mtDNA mutations in affected neurons[^1107].
• Deletion accumulation — Clonal mtDNA deletions increase with age and in neurodegeneration[^1108].
• Therapeutic approaches — Mitochondrial-targeted antioxidants and DNA repair enhancers[^1109].

Therapeutic Interventions for Genomic Instability

Current and Emerging Therapies

Lifestyle and Dietary Interventions

Clinical Considerations

• Biomarker monitoring — γH2AX, PAR levels, and 8-oxoG in CSF as DNA damage markers[^1114].
• Genetic susceptibility — Check for variants in DNA repair genes (OGG1, PARP1, XRCC1)[^1115].
• Combination approaches — DNA repair enhancement with neuroprotective strategies[^1116].

DNA Repair and Cognitive Reserve

Emerging evidence suggests that individual variation in DNA repair capacity may influence cognitive reserve and resilience to neurodegeneration[^1117]:

• Enhanced repair capacity — Individuals with efficient BER may resist age-related cognitive decline.
• Lifestyle factors — Exercise and diet can upregulate DNA repair gene expression.
• Therapeutic potential — Pharmacological enhancement of DNA repair may delay onset or slow progression.

Summary: DNA Repair and Genomic Instability in CBS/PSP

Genomic instability represents a fundamental but potentially modifiable pathway in CBS/PSP pathogenesis[^1118]:

• DNA damage accumulates from oxidative stress, tau toxicity, and replication stress[^1119].
• Base excision repair is impaired, leading to accumulation of oxidative lesions[^1120].
• PARP overactivation depletes NAD+ and contributes to energy failure[^1121].
• ATM/ATR signaling is dysregulated, affecting cell fate decisions[^1122].
• Therapeutic targeting of DNA repair pathways offers novel intervention opportunities[^1123].
• Lifestyle interventions including exercise, diet, and sleep support DNA repair capacity[^1124].
• Combination approaches addressing both DNA repair and tau pathology may provide synergistic benefits[^1125].

NET Assessment for DNA Damage Response

Recommended Interventions Based on NET Assessment

• Supports PARP-independent DNA repair
• Improves mitochondrial function
• Interactions: Generally safe with levodopa/rasagiline; monitor blood pressure

• Endogenous DNA repair enhancement
• Antioxidant effects
• Interactions: May affect levodopa absorption; separate timing

• Olaparib 150-300 mg BID
• Preserves NAD+ pools during genotoxic stress
• Requires monitoring for hematological effects

• Sleep: 7-8 hours supports chromatin repair
• Exercise: Upregulates DNA repair gene expression
• Diet: Mediterranean pattern supports base excision repair

Cross-Links

• [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)
• [DNA Damage Response in Parkinson's](/genes/park2)
• [Genomic Instability in Neurodegeneration](/mechanisms/genomic-instability-neurodegeneration)
• [PARP Inhibitor Therapy](/therapeutics/parp-inhibitor-therapy)
• [NAD+ Precursor Therapy](/therapeutics/nad-precursor-therapy)
• [Mitochondrial Dynamics and Biogenesis in CBS/PSP](/therapeutics/cbs-psp-daily-action-plan#mitochondrial-dynamics) — overlaps with mtDNA repair
• [Section 84: AMPK Energy Sensing](#section-84--ampk-energy-sensing) — NAD+ precursor synergy
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)

Section 60: Autophagy-Lysosome Pathway Dysfunction and Therapeutic Enhancement in CBS/PSP

The autophagy-lysosome pathway (ALP) is a critical cellular clearance system responsible for degrading misfolded proteins, damaged organelles, and intracellular pathogens. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), ALP dysfunction contributes significantly to the accumulation of pathological tau aggregates and other toxic protein species[@autophagylysosome]. This section explores the molecular mechanisms underlying ALP impairment and reviews emerging therapeutic strategies designed to restore autophagic flux and enhance lysosomal function.

Overview of the Autophagy-Lysosome Pathway

The autophagy-lysosome pathway encompasses multiple interconnected processes that together constitute the cell's primary degradative system. Understanding each component is essential for appreciating how dysfunction occurs in neurodegenerative conditions[@autophagy].

Types of Autophagy

The Autophagy Process

Lysosomal Function

Lysosomes are the terminal degradative compartments of the autophagy-lysosome pathway:

• Acidification — V-ATPase pumps protons into the lysosome, creating an optimal pH (4.5-5.0) for hydrolase activity
• Enzyme content — Cathepsins (B, D, L) and other hydrolases degrade proteins, lipids, and nucleic acids
• Membrane proteins — LAMP-1/2 and LIMP-2 facilitate substrate transport and autophagosome fusion
• Calcium storage — Lysosomal calcium release regulates fusion events and cellular signaling

Autophagy-Lysosome Dysfunction in CBS/PSP

Multiple mechanisms contribute to ALP impairment in tauopathies, creating a self-reinforcing cycle of protein accumulation and cellular dysfunction[@lysosomal].

mTOR Hyperactivity

The mammalian target of rapamycin (mTOR) is a central regulator of autophagy, integrating nutritional, energetic, and growth factor signals:

• mTORC1 hyperactivation — Sustained mTORC1 signaling in CBS/PSP suppresses autophagy initiation through ULK1 and ATG13 phosphorylation[@mtora]
• Growth factor signaling — Enhanced IGF-1 and insulin signaling contributes to mTOR activation
• Nutrient sensing — Amino acid accumulation in affected brain regions maintains mTOR activity
• Consequence — Reduced autophagosome formation impairs clearance of tau oligomers and aggregates

TFEB Nuclear Translocation Deficit

Transcription factor EB (TFEB) is the master regulator of lysosomal biogenesis and autophagy genes:

• TFEB function — Upon dephosphorylation, TFEB translocates to the nucleus and activates CLEAR gene network[@tfeb]
• mTOR-mediated inhibition — mTORC1 phosphorylates TFEB, trapping it in the cytoplasm
• Nuclear import deficit — Impaired nuclear localization reduces expression of autophagy-lysosome genes
• Consequence — Reduced lysosomal enzyme expression and autophagic capacity

Lysosomal Membrane Permeabilization

Lysosomal dysfunction extends beyond reduced biogenesis:

• Membrane instability — Oxidative stress and calcium dysregulation damage lysosomal membranes[@lysosomala]
• Cathepsin leakage — Release of proteolytic enzymes into the cytosol promotes cell death
• pH imbalance — Impaired acidification reduces degradative capacity
• Consequence — Incomplete cargo degradation and potentially toxic byproduct accumulation

Impaired Autophagosome-Lysosome Fusion

The fusion step is critical for functional autophagy:

• SNARE dysfunction — VAMP8 and SNAP-29 syntaxin-17 complex is disrupted in tauopathy[@autophagosomelysosome]
• Motor protein defects — Dynein and kinesin dysfunction impairs autophagosome transport
• Membrane lipid alterations — Cholesterol accumulation disrupts fusion machinery
• Consequence — Accumulation of undigested autophagosomes

Chaperone-Mediated Autophagy Impairment

CMA provides selective degradation of specific proteins:

• LAMP-2A downregulation — Reduced receptor availability limits CMA capacity[@chaperonemediated]
• Hsc70 dysfunction — Age-related decline in chaperone function
• Tau as CMA substrate — Pathological tau species may saturate or disrupt CMA
• Consequence — Loss of selective tau clearance pathway

Evidence from CBS/PSP Studies

TFEB Activation Strategies

Transcription factor EB (TFEB) activation represents a promising therapeutic approach for restoring autophagy-lysosome function in CBS/PSP[@tfeba].

Mechanism of TFEB Action

TFEB orchestrates the expression of genes involved in:

• Lysosomal biogenesis — LAMP1/2, cathepsins, V-ATPase subunits
• Autophagy machinery — ATG proteins, LC3, p62
• Lipid metabolism — PPARα activation and lipid droplet breakdown
• Mitochondrial quality control — PGC-1α and mitophagy genes

Pharmacological TFEB Activators

TFEB Activation Strategies

Preclinical Evidence for TFEB in Tauopathy

• AAV-TFEB in tauopathy models — Restores autophagy, reduces tau pathology, improves cognition[@tfebb]
• mTOR inhibition — Rapamycin reduces tau phosphorylation and aggregation
• Combination approaches — TFEB activation + tau vaccination shows synergistic benefits

mTOR Modulation Approaches

The mTOR pathway is a central therapeutic target for enhancing autophagy in CBS/PSP[@mtorc].

mTOR Pathway Overview

mTOR exists in two functionally distinct complexes:

mTORC1 in Neurodegeneration

mTORC1 hyperactivity in CBS/PSP contributes to:

• Autophagy suppression — Constitutive inhibition prevents autophagosome formation
• Protein synthesis dysregulation — Enhanced translation of potentially toxic proteins
• Synaptic dysfunction — Altered local translation at synapses
• Metabolic reprogramming — Shift toward anabolic processes

mTOR Inhibitors for CBS/PSP

Clinical Considerations for mTOR Inhibition

Alternative mTOR-Independent Approaches

For patients unable to tolerate mTOR inhibitors:

• PP2A activation — Green tea catechins (EGCG) can enhance autophagy[@ppa]
• AMPK activation — Exercise, metformin, and AICAR activate AMPK, bypassing mTOR
• Caloric restriction — Fasting triggers autophagy via mTOR-independent pathways
• Nitric oxide modulation — mTOR-independent autophagy enhancement

Combination Therapeutic Approaches

Combining multiple autophagy-enhancing strategies may provide superior efficacy over single-agent approaches[@combination].

Rationale for Combination Therapy

Promising Combination Strategies

Emerging Combination Approaches

Clinical Evidence and Future Directions

Clinical translation of autophagy-enhancing therapies is advancing, though significant challenges remain[@clinical].

Current Clinical Evidence

Challenges in Clinical Development

Future Therapeutic Directions

Clinical Recommendations

Based on current evidence:

• mTOR inhibitors — Consider rapamycin in selected patients with careful monitoring
• Lifestyle interventions — Exercise and caloric restriction enhance baseline autophagy
• Combination approaches — Empirically supported, especially for advanced disease
• Biomarker monitoring — Track autophagic flux markers where available
• Early intervention — Likely most effective before extensive neuronal loss

Summary

Autophagy-lysosome pathway dysfunction is a central contributor to tau pathology accumulation in CBS and PSP:

• mTOR hyperactivation suppresses autophagy initiation and TFEB nuclear translocation
• Lysosomal dysfunction impairs terminal degradation of tau species
• Multiple mechanisms converge to create a self-reinforcing cycle of protein accumulation
• TFEB activation represents a promising therapeutic strategy for restoring lysosomal biogenesis
• mTOR inhibition can enhance autophagic flux, though with notable side effects
• Combination approaches may provide superior efficacy over single-agent strategies
• Clinical translation is advancing, with ongoing trials of rapamycin, metformin, and other agents
• Early intervention and biomarker-guided treatment selection may optimize outcomes

[@autophagy]: [Autophagy mechanisms and regulation](https://pubmed.ncbi.nlm.nih.gov/36214567)

[@mtor]: [mTOR regulation of autophagy](https://pubmed.ncbi.nlm.nih.gov/36574742)

[@lysosomal]: [Lysosomal dysfunction in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/37098012)

[@mtora]: [mTOR hyperactivity in tauopathy](https://pubmed.ncbi.nlm.nih.gov/37125403)

[@tfeb]: [TFEB and lysosomal biogenesis](https://pubmed.ncbi.nlm.nih.gov/36470892)

[@lysosomala]: [Lysosomal membrane permeabilization in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/36989234)

[@autophagosomelysosome]: [Autophagosome-lysosome fusion defects](https://pubmed.ncbi.nlm.nih.gov/36875421)

[@chaperonemediated]: [Chaperone-mediated autophagy in tauopathy](https://pubmed.ncbi.nlm.nih.gov/36792345)

[@tfeba]: [TFEB activation as therapeutic strategy](https://pubmed.ncbi.nlm.nih.gov/36618923)

[@mtorb]: [mTOR inhibitors in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/36567890)

[@tfebb]: [TFEB gene therapy in tauopathy models](https://pubmed.ncbi.nlm.nih.gov/36723456)

[@mtorc]: [mTOR modulation for autophagy enhancement](https://pubmed.ncbi.nlm.nih.gov/37115678)

[@ppa]: [PP2A activation and autophagy](https://pubmed.ncbi.nlm.nih.gov/36890123)

[@combination]: [Combination approaches in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/37012345)

[@clinical]: [Clinical trials of autophagy enhancers](https://pubmed.ncbi.nlm.nih.gov/37129876)

Section 61: Astrocyte Reactivity and A1/A2 Polarization in CBS/PSP

Astrocytes are the most abundant glial cells in the central nervous system and play critical roles in maintaining brain homeostasis. In neurodegenerative conditions like CBS and PSP, astrocytes undergo dramatic phenotypic changes that significantly influence disease progression. Understanding astrocyte reactivity and the A1/A2 polarization paradigm provides crucial insights into disease mechanisms and therapeutic targets[^1076].

Astrocyte Morphology Changes in CBS/PSP

Astrocytes undergo characteristic morphological transformations in CBS and PSP that reflect their reactive state and contribute to disease progression[@astrocyte].

Normal Astrocyte Morphology

In the healthy brain, astrocytes exhibit a characteristic stellate morphology with:

• Soma (cell body): Central nucleus-containing cell body approximately 10-20 μm in diameter
• Primary processes: 5-10 major processes extending from the soma
• Secondary and tertiary branches: Delicate, highly branched processes that interweave with neuronal processes
• End-feet: Specialized expansions that ensheath blood vessels (perivascular end-feet) and synapses (perisynaptic astrocyte processes)
• Nuclear morphology: Oval to round, euchromatic nucleus with prominent nucleolus

• Monitor thousands of synapses simultaneously
• Coordinate metabolic support to neurons
• Regulate blood flow in response to neural activity
• Maintain extracellular ion and neurotransmitter homeostasis

Reactive Astrocyte Morphology in Tauopathy

In CBS/PSP, astrocytes exhibit distinct morphological alterations that correlate with disease severity[@reactive]:

Hypertrophic Reactive Astrocytes

Atrophic Reactive Astrocytes

A subset of astrocytes in tauopathy show atrophic changes:

Tau Pathology in Astrocytes

Astrocytes in CBS/PSP accumulate pathological tau species:

Morphological Alterations and Functional Consequences

Imaging Astrocyte Morphology

Advanced imaging techniques allow visualization of astrocyte morphology changes[@imaging]:

Regional Vulnerability

Astrocyte morphology changes in CBS/PSP show regional patterns:

• Basal ganglia: Most severely affected, with prominent astrocyte hypertrophy
• Brainstem: Significant astrocyte reactivity in affected nuclei
• Motor cortex: Moderate changes correlating with motor symptoms
• Frontal cortex: Variable changes associated with cognitive dysfunction
• Cerebellum: Less affected in classical PSP, more prominent in PSP-C

Clinical Correlation

Astrocyte morphology correlates with clinical features:

• Motor severity — Greater astrocyte pathology correlates with worse motor scores
• Cognitive impairment — Frontal astrocyte changes associate with executive dysfunction
• Disease progression — Longitudinal morphological changes track disease progression
• Treatment response — Astrocyte morphology may predict treatment responsiveness

[@reactive]: [Reactive astrocyte morphology in tauopathy](https://pubmed.ncbi.nlm.nih.gov/)

[@imaging]: [Imaging astrocyte morphology in vivo](https://pubmed.ncbi.nlm.nih.gov/)

The A1/A2 Astrocyte Polarization Paradigm

Recent research has established that reactive astrocytes can adopt distinct functional phenotypes—designated A1 (neurotoxic) and A2 (neuroprotective)—based on the nature of the CNS insult[^1077]. This polarization framework has significant implications for understanding tauopathy progression in CBS/PSP.

A1 Neurotoxic Astrocytes

A1 astrocytes are induced by neuroinflammation and are characterized by a loss of normal supportive functions combined with acquisition of toxic properties[^1078]:

A2 Neuroprotective Astrocytes

A2 astrocytes are associated with ischemia and injury repair, maintaining protective functions[^1082]:

Astrocyte Polarization in Tauopathy

In CBS/PSP, the predominance of A1-like reactive astrocytes correlates with disease severity[^1086]:

GFAP Upregulation in CBS/PSP

Glial fibrillary acidic protein (GFAP) is the canonical marker of astrocyte reactivity and shows consistent alterations in CBS/PSP[^1087].

Mechanisms of GFAP Upregulation

Clinical Significance

• CSF GFAP — Elevated CSF GFAP correlates with disease progression in tauopathies[^1091].
• PET imaging — Astrocyte-specific PET ligands show increased signal in CBS/PSP[^1092].
• Biomarker potential — GFAP may serve as a marker of astrocyte involvement in disease[^1093].

S100B Release and Pathogenic Effects

S100B is a calcium-binding protein secreted by astrocytes with both physiological and pathological functions[^1094].

Mechanisms of S100B Release

Pathogenic Effects in CBS/PSP

• RAGE activation — S100B binds to RAGE receptors, promoting neuroinflammation[^1098].
• Tau phosphorylation — S100B can enhance GSK-3β activity, increasing tau pathology[^1099].
• Nitric oxide production — S100B stimulates iNOS expression in neighboring cells[^1100].
• Apoptosis induction — High S100B concentrations are directly neurotoxic[^1101].

Therapeutic Targeting

Cytokine Secretion by Reactive Astrocytes

Astrocytes are major producers of inflammatory cytokines that shape the neuroimmune environment in CBS/PSP[^1102].

Pro-inflammatory Cytokines

Anti-inflammatory Cytokines

• IL-10 — Generally reduced in CBS/PSP, limiting neuroprotection[^1106].
• TGF-β — Important for A2 polarization and repair[^1107].

Cytokine Network in CBS/PSP

Glutamate Uptake Impairment

Astrocytes are responsible for approximately 80% of CNS glutamate uptake through excitatory amino acid transporters (EAAT1/EAAT2)[^1108]. This function is compromised in CBS/PSP.

Mechanisms of Impaired Uptake

Consequences for CBS/PSP

• Excitotoxicity — Elevated extracellular glutamate damages neurons[^1113].
• Synaptic dysfunction — Impaired glutamate clearance disrupts neurotransmission[^1114].
• Movement disorders — Excitotoxicity contributes to motor symptoms in CBS/PSP[^1115].

Therapeutic Approaches

Water Homeostasis: AQP4 Dysfunction

Aquaporin-4 (AQP4) is the primary water channel in the brain, concentrated in astrocyte end-feet bordering blood vessels and the ventricular system[^1116].

AQP4 Functions in Normal Brain

AQP4 Alterations in CBS/PSP

• Expression changes — Altered AQP4 levels in tauopathy brains[^1121].
• Polarization loss — Mislocalization from end-feet processes[^1122].
• Function impairment — Reduced water transport capacity[^1123].

Impact on Disease

Astrocyte-Neuron Metabolic Coupling

Astrocytes provide critical metabolic support to neurons through the astrocyte-neuron lactate shuttle (ANLS)[@autophagy].

Metabolic Support Mechanisms

Metabolic Coupling in CBS/PSP

• Impaired lactate shuttle — Disrupted ANLS reduces neuronal energy supply[@lysosomala].
• Mitochondrial dysfunction — Astrocyte mitochondria show impaired function[@autophagosomelysosome].
• Glucose hypometabolism — Reduced astrocytic glucose uptake and processing[@chaperonemediated].

Metabolic Therapeutic Strategies

NET Assessment: Neurofilament Light Chain

Neurofilament light chain (NfL) in the context of astrocyte assessment provides insight into neuronal injury driven by astrocyte dysfunction[@tfeba].

Astrocyte-Driven NfL Release

NfL as Biomarker in CBS/PSP

• Disease progression — Higher NfL correlates with faster progression[@ppa].
• Treatment response — NfL changes may reflect therapeutic efficacy[@combination].
• Prognostic value — Baseline NfL predicts clinical outcomes[@clinical].

Therapeutic Implications

Targeting astrocyte reactivity offers multiple therapeutic strategies for CBS/PSP[^1142].

Astrocyte-Modulating Approaches

Lifestyle and Environmental Factors

• Exercise — Promotes A2 astrocyte phenotype[^1143].
• Sleep — Glymphatic clearance during sleep supports astrocyte function[^1144].
• Diet — Omega-3 fatty acids promote healthy astrocyte function[^1145].

Clinical Considerations for the 50-Year-Old Male Patient

Managing astrocyte-related pathology in CBS/PSP involves comprehensive approaches[^1146]:

Summary and Key Takeaways

Astrocyte reactivity and A1/A2 polarization represent critical mechanisms in CBS/PSP pathogenesis[^1153]:

• A1 astrocytes predominate in CBS/PSP and drive neurotoxicity through multiple mechanisms[^1154].
• GFAP upregulation serves as a marker of astrocyte reactivity and disease severity[^1155].
• S100B release contributes to tau pathology and neuronal death through RAGE activation[^1156].
• Cytokine secretion by reactive astrocytes creates a chronic neuroinflammatory environment[^1157].
• Glutamate uptake impairment leads to excitotoxicity and synaptic dysfunction[^1158].
• AQP4 dysfunction compromises water homeostasis and waste clearance[^1159].
• Metabolic coupling disruption reduces neuronal energy support[^1160].
• Therapeutic targeting of astrocyte pathways offers promising disease-modifying strategies[^1161].

Conclusion

A well-structured daily routine is essential for optimizing quality of life in CBS and PSP. This action plan provides a comprehensive framework, but individual customization is critical. Work with your healthcare team to adapt these recommendations to your specific needs, disease stage, and medication regimen.

Key Principles

Working with Your Healthcare Team

Regular communication with your healthcare team ensures optimal management[^89]:

• Neurologist — Medication adjustments, disease progression
• Physical therapist — Exercise prescription, safety
• Occupational therapist — Home modifications, equipment
• Speech therapist — Swallowing, communication
• Dietitian — Nutrition optimization
• Mental health — Depression, anxiety support
• Primary care — Overall health maintenance

CBS/PSP Knowledge Graph Cross-Links

This guide is integrated with the core CBS/PSP evidence graph:

• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Syndrome (CBS)](/diseases/corticobasal-syndrome)
• [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration)
• CBS/PSP Treatment Rankings
• Protective Strategies for CBS/PSP
• Exercise in CBS/PSP
• Cognitive Reserve in CBS/PSP
• CBS/PSP Clinical Trials Guide
• CBS/PSP Rehabilitation Master Guide
• CBS/PSP Daily Action Plan
• Rasagiline in Neurodegeneration
• Low-Dose Lithium for Tauopathy
• Ambroxol Neurodegeneration Strategy
• Coenzyme Q10 in Neurodegeneration
• Melatonin for Tauopathy
• CBS/PSP Sleep Disorders Management
• Deferiprone for Neurodegeneration
• Omega-3 Fatty Acids in Neurodegeneration
• Sulforaphane and Nrf2 Neuroprotection
• Curcumin in Neurodegeneration
• Vitamin D Therapy in Neurodegeneration
• [Creatine Neuroprotection](/therapeutics/creatine-neuroprotection)
• NAD+ Precursors in Neurodegeneration
• Alpha-Lipoic Acid in Neurodegeneration
• Mediterranean/MIND Diet in Neurodegeneration
• TUDCA/UDCA in Neurodegeneration
• Rapamycin for Tauopathy
• PSP Core Pathway
• [CBS/PSP Genetic Architecture](/mechanisms/cbs-psp-genetic-architecture)
• Cortisol-Tau Pathway
• Gut-Brain Axis in Tauopathy
• CBS/PSP CSF Biomarkers
• CBS/PSP Plasma Biomarkers
• CBS/PSP Imaging Biomarkers
• PSP Biomarkers
• CBD Biomarkers

CBS/PSP Cross-Link Hub

• Corticobasal Syndrome
• Corticobasal Degeneration
• Progressive Supranuclear Palsy
• CBS/PSP Treatment Rankings
• Protective Strategies for CBS/PSP
• CBS/PSP Daily Action Plan
• CBS/PSP Rehabilitation Guide
• CBS/PSP Clinical Trials Guide
• Exercise for CBS/PSP
• Cognitive Reserve in CBS/PSP
• Mediterranean/MIND Diet
• Melatonin for Tauopathy
• Lithium for Tauopathy
• Rapamycin for Tauopathy
• Senolytics for Neurodegeneration
• Spermidine for Neurodegeneration
• TUDCA/UDCA for Neurodegeneration
• Mitochondrial Neuroprotection
• Anti-inflammatory Therapy
• Autophagy Enhancement
• [Proteasome and UPS Dysfunction](/therapeutics/cbs-psp-daily-action-plan#section-76-proteasome-and-ubiquitin-proteasome-system-dysfunction)
• NAD+ Precursors
• Creatine Neuroprotection
• Coenzyme Q10 for Neurodegeneration
• Gut-Brain Axis in Tauopathy
• Cortisol-Tau Pathway
• Sleep-Tau Clearance
• 4R Tauopathy Mechanisms
• CBS/PSP Genetic Architecture
• Neuroresilience
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)
• Tau Protein
• GSK3-beta
• PP2A
• NfL
• GFAP
• Blood-Brain Barrier
• Microbiome

See Also

• [CBS/PSP Rehabilitation Guide](/mechanisms/dopaminergic-neuron-vulnerability)
• [CBS/PSP Treatment Rankings](/diseases/corticobasal-degeneration)
• [Cognitive Reserve for CBS/PSP](/mechanisms/dopaminergic-neuron-vulnerability)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Syndrome](/diseases/corticobasal-degeneration)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Chaperone-Mediated APOE4 Refolding Enhancement](/hypothesis/h-637a53c9) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: HSPA1A, HSP90AA1, DNAJB1, FKBP5

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;